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ABSTRACT 
Breakthroughs in the understanding of the basic biology of 
melanoma have yielded continue progresses on a variety of fronts. 
In the past decade, several specific inhibitors have been utilized 
against melanoma. However, after a short period of remission, their 
clinical use inevitably evidenced drug resistance and disease 
exacerbation. Finding new arms against the advanced phase of 
melanoma is one of the major challenges in the struggle against this 
cancer. New insight highlighted the rewiring of cellular signaling 
and the reprogramming of metabolic pathways in cancer. In normal 
cells a precise balance between saturated and unsaturated Fatty Acid 
(FA) synthesis is required for maintaining cell homeostasis. 
Conversely the anabolic pathways responsible for constructing 
these molecules appear altered during tumorigenesis. It is now 
appreciated the importance of fatty acid regulation in malignant 
disease and the opportunities to target these pathways, required not 
only for cell growth and division, but also for tumor dissemination.  
The role of the stearoyl-CoA desaturase 5 (SCD5) was investigated 
in melanoma, being its pathophysiological function virtually 
unknown. This enzyme, converting saturated into monounsaturated 
FAs, is downregulated during progression of melanoma by 
epigenetic and miR221/-222-dependent mechanisms. SCD5 
restored expression significantly reduced melanoma malignancy, in 
human A375M melanoma and in murine 4T1 mammary carcinoma 
cell lines, mainly by inducing oleic acid.  In both cell systems we 
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also evidenced SCD5 effects on tumor microenvironment, through 
reduced secretion of protumoral protein such as the Secreted Protein 
Acidic and Rich in Cysteine (SPARC), Collagen IV and Cathepsin 
B. The net effect of SCD5 action was evidenced by the intracellular 
acidification (pHe > pHi) and, in turn, by the inhibition of the 
vesicular trafficking across plasma membranes.  This acidification 
also depends on SCD5-induced reduction of the C2 subunit of the 
proton pump vacuolar H+-ATPase. Supplementation of oleic acid 
was per se able to mimic SCD5 enforced expression by reducing the 
protumoral matrix protein secretion.  
Our data support a role for SCD5 and its enzymatic product, oleic 
acid, in protection against malignancy, offering an explanation for 
the beneficial Mediterranean diet. Furthermore, SCD5 appears to 
functionally connect tumor cells and the surrounding stroma, with 
consequences on tumor spread and eventually resistance to 
treatment.  
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INTRODUCTION 
1. MELANOMA 
Melanocytic neoplasms range from benign lesions, termed 
melanocytic naevi, to malignant ones, termed melanomas. All 
originate from melanocytes, neural crest-derived cells, that during 
development colonize the skin, eye and a board range of other 
tissues throughout the body (Mort RL., 2015). The incidence of 
melanoma has more than doubled in the white population over the 
last 30 years, and melanoma currently is the sixth most common 
cancer in the United States (American Cancer Society, 2016). and it 
still continues increasing (Fig. 1). At present melanoma represents 
the tenth most common cancer in men and the seventh in women 
(Rapporto AIOM-AIRTUM 2015).  
 
 
 
 
 
Fig 1: Expected incidence rate of melanoma, United States 1975-
2020 
www.cdc.gov/cancer  
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While melanoma accounts for roughly 4% of all skin cancers, it is 
responsible for nearly 75% of skin cancer deaths. Treatment of 
melanoma in its early stages provides the best opportunity for cure. 
The most common types of melanoma in Caucasians are found on 
sun-exposed skin. This cutaneous melanomas can be broadly 
categorized by their origins from skin that is or not chronically sun 
damaged (CSD) and non-CSD melanomas, respectively.  
CSD and non-CSD melanomas differ in their anatomical sites of 
origin, degree of cumulative exposure to ultraviolet (UV) radiation, 
host age, mutation burden and types of oncogenic alteration (Shain 
AH., 2016). CSD melanomas arise on skin that shows macroscopic 
and microscopic signs of long-term exposure to UV radiation, 
specifically marked solar elastosis. Thus CSD melanomas typically 
originate from the head, the neck and the dorsal surfaces of the 
distal extremities of older individuals (>55 years of age). They have 
a high mutation burden and are associated with neurofibromin 1 
(NF1), Neuroblastoma RAS Viral Oncogene Homolog (NRAS), B-
Raf Proto-Oncogene, Serine/Threonine Kinase (BRAF) nonV600E 
or KIT Proto-Oncogene Receptor Tyrosine Kinase (KIT) mutations.  
In contrast, non-CSD melanomas typically affect the more 
intermittently sun-exposed areas such as the trunk and proximal 
extremities of younger individuals (<55 years of age) that do not 
show marked solar elastosis. They are associated with a moderate 
mutation burden and a predominance of BRAF V600E mutations 
(Bastian BC., 2014). Primary melanomas are often found in 
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association with different types of precursor lesions, ranging from 
benign naevi and dysplastic naevi to melanoma in situ. Idealized 
progression models often imply a single path of evolution from 
naevus, to dysplastic naevus, to melanoma in situ, to invasive 
melanoma (Fig. 2).  
 
 
 
 
 
 
 
 
Fig 2:  The morphological spectrum of melanocytic neoplasms. 
(A) Clinical images showing a free-standing naevus, a dysplastic naevus, 
melanoma in situ and invasive melanoma, with schematics illustrating the 
architectural features for each type of lesion and (B) histopathological 
features. (Adapted from Shain AH, Nat Rev Cancer. 2016)  
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1.2. RISK FACTORS 
There is a complex interactions between exogenous environmental 
and endogenous factors (Cohen C., 2002; Maldonato JL., 2003). 
The most relevant environmental factor is intermittent sun 
exposure, while intrinsic factors are represented by individual's 
family history and inherited genotypes.  
Although up to 65% of malignant melanomas may be related to sun 
exposure, the role of chronic sun exposure is still controversial in 
view of host factors such as skin and hair color (see Fitzpatrick skin 
classification, (Table 1).  
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Moreover the development of melanoma among albinos is a very 
rare occurrence (Perry PK. 2001), which further questions the role 
of UV light in melanoma genesis. A multifactorial model of 
cancerogenesis with complex interactions between genes and 
environment is likely to be the explanation for these apparently 
conflicting evidences.  
Other risk factors in developing melanoma include:  
-dysplastic naevi which are histologically characterized by the 
presence of an architectural disorder with some fusion of rete 
ridges, lymphocytic infiltrate in the upper dermis and nuclear atypia 
of the melanocytes in the nest (Hussein MR., 2005, Naeyaert JM., 
2003). Naevi number is a very useful intermediate phenotype for 
melanoma as it is to date the highest risk factor for this tumor and 
this trait can easily be documented in all Caucasian populations 
whilst melanoma is rare.  
-race: as melanoma is much more frequent in whites, being the 
proportion between Caucasians and Asian/Black population about 
20:1 (Balch CM., 2003). In non-whites melanoma is rare and 
mostly confined to non pigmented sites such as the subungual 
regions, the palms of the hand and the soles of the feet. Although 
the incidence is lower, the mortality rate in non-white patients is 
higher, which might be due to late diagnosis. 
-phototype: malignant melanoma risk is more than doubled in 
people with skin phototype I compared with skin phototype IV 
(Olsen CM., 2010) (for skin phototype features see Table 1).  
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1.2.1. SPORADIC MELANOMA 
Over the past decade, it has become evident that subsets of 
melanoma can be defined at molecular level by recurrent "driver" 
mutations that occur in multiple oncogenes, mainly BRAF, NRAS, 
Mitogen-Activated Protein Kinase Kinase 1 (MEK1) and KIT 
(Table 2). Such driver mutations lead to constitutive activation of 
mutant signaling proteins that induce specific pathways sustaining 
tumorigenesis (My cancer genome, 2016).  
 
 
 
The activation of Mitogen-Activated Protein Kinases (MAPK) 
pathway through mutations of BRAF appears to be the most 
common. Although the activation of the MAPK signaling (Fig. 3) 
has been recognized as a critical event, Khavari and colleagues have 
demonstrated that activation of BRAF–MAPK requires concomitant 
PI3K–AKT pathway alteration to affect melanoma development 
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(ChudnovskyY., 2005). Consistent with these data, over 60% of 
human melanomas exhibit activated AKT (Dhawan P., 2002) and 
mutational inactivation and/or deletion of the PI3K negative 
regulator PTEN occurring in 30–40% of melanoma cell lines (Sherr 
CJ., 2001). 
 BRAF 
The most prevalent BRAF mutations detected in melanoma are 
missense that introduce an amino acid substitution at valine 600. 
Approximately 80–90% of V600 BRAF mutations are V600E 
(valine to glutamic acid), while 5-12% are V600K (valine to lysine) 
and 5% or less are V600R (valine to arginine) or V600D (valine to 
aspartic acid) (Lovly CM., 2012). The result of these mutations is to 
enhance BRAF kinase activity increasing phosphorylation of 
downstream targets, particularly MEK (Wan PT., 2004). In the vast 
majority of cases, BRAF mutations are non-overlapping with other 
oncogenic mutations found in melanoma (e.g., NRAS mutations, 
KIT mutations, etc.). Clinically, BRAF inhibitors have been 
investigated in combination with MEK inhibitors in subsets of 
patients with BRAF V600E mutation-positive melanoma previously 
resistant to BRAF inhibitors (Johnson DB., 2014; Ribas A., 2014). 
 NRAS 
In the majority of cases these mutations are missense mutations 
which introduce an amino acid substitution at positions 12, 13, or 
61. The result of these mutations is constitutive activation of NRAS 
signaling pathways. NRAS mutations are found in all melanoma 
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subtypes, but may be slightly more common in melanomas derived 
from chronic sun-damaged skin (Ball NJ., 1994). 
 MEK1 
The prevalence of MEK1 mutations in different melanoma subtypes 
is not yet known. However, most  of the reported MEK1 mutations 
involve C>T and G>A nucleotide changes, which frequently result 
from exposure to UV radiation (Nikolaev SI., 2012). 
 KIT 
Somatic point mutations in melanoma tumor specimens have been 
detected predominantly in the juxtamembrane domain, but also in 
the kinase domain of KIT. They can induce ligand-independent 
receptor dimerization, constitutive kinase activity and in turn 
transformation (Growney JD., 2005).  
 
 
 
 
Fig 3:  MAPK pathway  
(Lovly et al.,  2015. My Cancer Genome) 
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1.2.2. FAMILIAR MELANOMA 
Intrinsic risk factors belong to the familiar melanoma, which 
include mutations or total loss of selected Tumor Suppressor Genes 
(TSGs). Familial melanoma patients tend to have an earlier age at 
first melanoma diagnosis, thinner tumors and higher frequencies of 
multiple primary melanomas (MPMs) respect to sporadic melanoma 
patients (Hansson J., 2008). A family history of melanoma greatly 
increases a person's risk because of mutations in three high-
penetrance and one low-penetrance melanoma predisposing genes. 
The best understood melanoma susceptibility gene is cyclin-
dependent kinase inhibitor 2A (CDKN2A) on chromosome 9. 
Hereditary mutations in this gene underlie susceptibility to 
melanoma in 40% of families with 3 or more cases of melanoma 
(Goldstein AM., 2007). The CDKN2A locus codes for two 
alternatively spliced products: p16 and p14ARF. P16 binds to 
CDK4 and is a cell cycle inhibitor (Kamb A., 1994) playing a role 
on cellular senescence, specifically inducing melanocyte senescence 
(Sviderskaya EV., 2003). P14ARF is a tumor suppressor gene too. 
Mutations at the CDKN2A locus may lead to melanoma 
susceptibility if they impact on p16 alone, p14ARF alone 
(Randerson-Moor JA., 2001; Rizos H., 2001), or on both p16 and 
p14ARF. Very rare families exist (2% of families with detectable 
mutations) who have hereditary mutations in the CDK4 gene which 
code for the p16 binding site (Goldstein AM., 2000; Zuo L., 1996). 
The lifetime risk (i.e. penetrance) of melanoma in CDKN2A 
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mutation carriers is high, but variable, ranging from 58% in Europe 
to 91% in Australia by the age of 80 years (Bishop DT., 2002), thus 
underscoring the importance of the environment (geographical 
location) even in familial melanoma.  
Mutations in these gene products are inherited in an autosomal 
dominant mechanism and confer ‘extremely high risk’ (Pho L., 
2006). Besides high-penetrance genes we can also find low-
penetrance genes, as the melanocortin receptor gene (MC1R), 
located on 16q24.3, which is established as a determinant of 
susceptible phenotypes such as red hair (Raimondi S., 2008), sun 
sensitivity in the absence of red hair (Healy E., 2000) and freckles 
(Bastiaens M., 2001). MC1R gene encodes the G-protein coupled 
receptor for α-melanocyte stimulating hormone (α-MSH) (Hayward 
NK., 2003). Binding of α-MSH to the receptor increases the 
expression of enzymes involved in the production of melanin in 
melanocytes. Other pigmentary genes as tyrosinase (TYR), TYR 
related protein 1 (TYRP1) agouti signalling protein, (ASIP) have 
been also recently identified as melanoma susceptibility genes 
(Gudbjartsson DF., 2008).  
 
1.3. DIAGNOSIS AND HYSTOLOGICAL CLASSIFICATION  
It is worth to mention the mnemonic of melanoma risk factors 
“ABCDE”. It is a simple but extremely important “must to know” 
that every health care giver should be familiar with since it may 
prevent a potentially curable atypical melanocytic proliferation from  
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progressing to malignant melanoma. These ABCDE are 
abbreviation for: ASYMMETRY, BORDER irregularity (map like 
configuration), COLOR variegation (more than one color: light-dark 
brown color is usually due to presence of melanin in epidermis, blue 
and black colors due to melanin in dermis; red color due to 
inflammation and white color due to fibrosis in regression), 
DIAMETER more than 0.6 cm and EVOLUTION (Healsmith MF., 
1994).  
For the diagnosis of malignant melanoma several other factors must 
be evaluated:  
•Type of melanoma  
•Thickness  
•Ulceration  
•Infiltration of vessels  
•Resection margins  
•Mitotic rate, or Clark`s level if mitotic rate cannot be determined 
reliably.  
•In addition, possible lymphocyte invasion, presence of necrosis, 
regression and neurotropism (tumor growth along nerves) should be 
considered. 
In 1967 malignant melanomas were originally classified by Dr. 
Wallace Clark and co-workers into several subtypes including. 
Superficial Spreading Melanoma (SSM), Nodular Malignant 
Melanoma (NMM) and Lentigo Malignant Melanoma (LMM). 
Later in 1976 Dr. Richard Reed added another subtype; i.e., Acral 
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Lentiginous Malignant Melanoma (ALMM). Histological criteria 
for diagnosing malignant melanoma subtypes is basically is related 
to the location of the melanocytes (lentiginous, Pagetoid, etc), 
organization pattern of melanocytes (nested or single cells), 
cytological features, location of malignant melanoma (for instance 
acral or subungual region) and other morphologic features such as 
lymphocytic host response.  
The major malignant melanoma subtypes are as follow:  
1) Superficial spreading melanoma (70%) is by far the most 
common type, accounting for about 70 percent of all cases. This is 
the one most often seen in young people. As the name suggests, this 
melanoma grows along the top layer of the skin for a fairly long 
time before penetrating more deeply. The first sign is the 
appearance of a flat or slightly raised discolored patch that has 
irregular borders and is somewhat asymmetrical in form. The color 
varies, and you may see areas of tan, brown, black, red, blue or 
white. This type of melanoma can occur in a previously benign 
mole. Melanomas can be found almost anywhere on the body, but is 
most likely to occur on the trunk in men, the legs in women, and the 
upper back in both.  
2) Nodular melanoma (15%) is usually invasive at the time it is 
first diagnosed. The malignancy is recognized when it becomes a 
bump. It is usually black, but occasionally is blue, gray, white, 
brown, tan, red or skin tone. The most frequent locations are the 
trunk, legs and arms, mainly of elderly people, as well as the scalp 
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in men. This is the most aggressive form of the melanomas.  
3) Lentigo maligna (10%) is similar to the superficial spreading 
type, as it also remains close to the skin surface for quite a while, 
and usually appears as a flat or mildly elevated mottled tan, brown 
or dark brown discoloration. This type of in situ melanoma is found 
most often in the elderly, arising on chronically sun-exposed, 
damaged skin on the face, ears, arms and upper trunk. Lentigo 
maligna is the most common form of melanoma in Hawaii. When 
this cancer becomes invasive, it is referred to as lentigo maligna 
melanoma. 
4) Acral lentiginous melanoma (5%) also spreads superficially 
before penetrating more deeply. It is quite different from the others, 
though, as it usually appears as a black or brown discoloration 
under the nails or on the soles of the feet or palms of the hands. This 
type of melanoma is sometimes found on dark-skinned people, and 
can often advance more quickly than superficial spreading 
melanoma and lentigo maligna. It is the most common melanoma in 
African-Americans and Asians, and the least common among 
Caucasians. (Skin Cancer Foundation).  
 
1.4. PROGNOSTIC FACTORS 
Malignant melanoma prognostic factors can be classified in three 
groups:  
A) Morphological (histology) factors 
B) Clinical Factors 
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C) Other Factors 
In the first group we include lots of different aspects, including 
Tumor thickness (T), Lymph node involvement (N), Distant 
metastasis (M), Ulceration, Regression, Mitotic rate, 
Lymphovascular invasion, Age, Histological type, Tumor 
infiltrating lymphocytes, Molecular markers. Tumor thickness is 
one of the most important prognostic available factors, together 
with nodal involvement and distant metastasis (see pTNM section) 
(Balch CM., 2001; Balch CM., 2004). In this field we can include 
1) the Breslow's system, which is based upon the measurement of 
the maximum thickness of melanoma from the granular layer of the 
epidermis to the deepest point of invasion into the dermis; 2) the 
Clark's levels describing melanoma depth according to the invasion 
of the four skin layers (level I confined to epidermis, level II with 
partial infiltration of the papillary dermis by single cells or small 
nests, level III characterized by the contact between tumor cells and 
papillary-reticular dermal interface, level IV with reticular dermis 
infiltration and level V characterized by subcutaneous fat 
infiltration). The Clark’s level is connected with the concept of 
Radial Growth Phase (RGP) and Vertical Growth Phase (VGP) 
which was introduce by Dr. Clark itself and his colleagues. 
Excluding some aggressive variants of nodular malignant 
melanoma, in general the pathology begins with an intra-epidermal 
proliferation of transformed melanocytes (RGP). This type of 
melanoma is always curable with surgical excision and can remains 
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confined for decades. When an aggressive infiltration of reticular 
dermis occurs we talk about VGP, that is defined as “dermal nests 
or expansive dermal nodule(s) composed of fully transformed 
malignant cells which exceeds the size of any junctional nest(s)”. 
The importance of the Vertical Growth Phase is connected with the 
fact that melanoma acquires the capability to metastasize, linking 
the prognosis with the depth of invasion.  
In particular the pTNM stages is able to identify four different 
groups with different pathological outcome.  
-Stage I: characterized by a good overall survival (OS) rates (5-year 
OS ≥90%), underlying the importance of early diagnosis;  
-Stage II: associated with a very variable outcome, the 5-year OS 
ranging from 45% (stage IIC) to 78% (stage IIA). The balance 
between this survival range is connected with the presence of 
ulcerations, adverse prognostic factors that shift patients with the 
same tumor thickness from stage IB to IIA (T2), from IIA to IIB 
(T3), and from IIB to IIC (T4). The impact on survival is evident as 
T4 melanoma (thickness >4 mm) is associated with a 67% 5-year 
OS rate when ulceration is absent (T4a, stage IIB), but the survival 
rate drops to 45% when ulceration is present (T4b, stage IIC). 
-Stage III: survival rates in part overlap with that of stage II (5-year 
OS rates range from 24% to 69%). With stage III disease, only 49% 
of all patients with nodal metastases survive 5 years (37% at 10 
years), but the range of melanoma-specific survival is large, going 
from 13% at 5 years for patients with the combination of the worst 
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risk factors (ulceration of the primary tumor, high regional lymph 
node burden) to 69% at 5 years for the most favorable prognostic 
factors. 
-Stage IV: characterized by a miserable prognosis, although some 
variability is found according to the site of metastasis and the lactate 
dehydrogenase (LDH) plasma levels (5-year OS rates range from 
9% to 18%).  
Of note, there is a significant variability in overall survival rates 
within each single TNM stage and substage (Fig. 4).  
 
 
 
 
 
 
 
 
Fig 4: American Joint Commitee on Cancer TNM stages and overall 
survival of patients with cutaneous melanoma (Molecula Melanoma 
Map Project)  
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1.5. TREATMENT OPTIONS 
Different type of treatment are available for melanoma patients:  
 
1.5.1. SURGERY 
Surgery removal of the tumor is the primary treatment of melanoma 
at all stages. A wide local excision is used to remove the tumor 
lesion and some of the normal tissue around it. If the tumor is 
removed very early, no other treatment is usually needed.   
 
1.5.2. TARGET THERAPY 
Targeted therapy is a form of treatment in which drugs are 
developed with the goal of destroying cancer cells while leaving 
normal cells intact. These drugs are designed to interfere with the 
specific molecules that are driving the growth and spread of the 
tumor. While BRAF inhibitor therapy is associated with clinical 
benefit in the majority of patients with BRAF V600E-mutated 
melanomas, resistance to treatment and tumor progression occurs in 
nearly all patients, usually in the first year (Sosman JA., 2012). A 
variety of mechanisms have been implicated in primary and 
acquired resistance to BRAF inhibitors, primarily through 
reactivation of the MAPK and other cell signaling pathways.  
 Vemurafenib (Zelboraf®) 
Was approved by the FDA in 2011 for the treatment of BRAF 
V600E mutant melanoma that cannot be removed by surgery. This 
drug is only approved for those patients who have tested positive 
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for the BRAF mutation. 
 Vemurafenib (Zelboraf®) + Cobimetinib (Cotellic®)  
Was approved by the FDA in November 2015 for the treatment of 
BRAF V600 mutant melanoma 
(https://clinicaltrials.gov/show/NCT02427893). Vemurafenib was 
previously approved in 2011 but in research studies, this 
combination showed improved progression-free and overall survival 
compared to Vemurafenib alone, (Larkin J., 2014) 
 Dabrafenib (Tafinlar®)  
was approved by the FDA in 2013 for the treatment of BRAF V600 
mutant melanoma that cannot be removed by surgery. This drug is 
only approved for those patients who have tested positive for the 
BRAF mutation. It is not indicated for the treatment of patients with 
wild-type BRAF mutation. 
 Trametinib (Mekinist®) 
was approved by the FDA in 2013 for the treatment of BRAF 
V600E or V600K mutations. It is a first-in-class MEK inhibitor 
approved for the treatment of unresectable or metastatic melanoma. 
It is not indicated for the treatment of patients who have received a 
prior BRAF inhibitor therapy. 
 Dabrafenib (Tafinlar®) + Trametinib (Mekinist®) 
received accelerated approval by the FDA in 2014 for 
demonstrating durable responses in patients with unresectable or 
metastatic melanomas that carry the BRAF V600E or V600K 
mutation. Randomized trials are in progress to assess the ability of 
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the combination to improve time to progression and overall survival 
compared with dabrafenib alone 
(https://clinicaltrials.gov/show/NCT02196181) (Robert C., 2015).  
 
1.5.3. IMMUNOTHERAPY 
Advanced melanomas that recur after surgery are difficult to treat 
with radiation and chemotherapy. New treatments, such as 
immunotherapies, offer benefits for these more advanced cancers. 
Immunotherapies stimulate the body’s immune system to attack 
cancer cells in various ways. Some forms of immunotherapy are 
already approved and routinely used to treat some melanomas, 
while others are still experimental (Seattle Cancer Care Alliance).  
 Interferon 
After surgery to remove melanoma, interferon is sometimes 
recommended to reduce the chance of melanoma returning. Another 
form of immune-stimulating treatment, but less powerful than 
ipilimumab, interferon is being tested in patients after surgery. 
While interferon has been a standard FDA-approved treatment for 
nonmetastatic melanoma following surgery, its ability to prevent 
relapse is very weak, and it causes many side effects (Seattle 
Cancer Care Alliance) 
 Interleukin-2 
A synthetic version of interleukin-2 (IL-2), a natural cytokine 
(protein that can stimulate the immune system), may be used to 
control advanced melanomas. Sometimes IL-2 is given along with 
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chemotherapy (Ridolfi R., 2002). It has been used for several 
decades and is sometimes used to treat patients whose melanoma 
has spread. The potential benefit is that some patients on this 
therapy may achieve long-term complete remission, but due to the 
potential for severe side effects IL-2 use is limited.  
 Tumor-Infiltrating Lymphocytes 
Tumor-infiltrating lymphocyte (TIL) therapy is another promising 
form of immunotherapy being investigated in people with stage IV 
melanoma. TILs are unique because they are immune system cells 
that naturally exist in people and that infiltrate melanoma tumors. 
TILs can recognize and attack melanoma cells, but melanoma 
responds by suppressing TILs and placing them in a sleeping state. 
Doctors can remove some suppressed TILs from the patient, 
reactivate them in the laboratory, grow them into billions, and then 
reinfuse them into the patient. The idea is that the high number of 
activated TILs will be able to attack the melanoma more effectively.  
Prior to the infusion of TILs, patients receive one week of 
lymphodepleting chemotherapy, which prepares their body by 
clearing out immune cells suppressed by their cancer and making 
space for the incoming TILs. After the TIL infusion, patients 
receive high-dose IL-2, which “feeds” the freshly infused TILs so 
they survive longer and attack cancer cells more effectively. The 
hospital stay for chemotherapy, TIL infusion, and high-dose IL-2 is 
around 10 to14 days (Seattle Cancer Care Alliance).  
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1.5.4. NEW IMMUNOTHERAPIES 
 Drugs anti CTLA-4 
In 2011, the U.S. Food and Drug Administration (FDA) approved 
ipilimumab (Yervoy®) to treat metastatic melanoma. It was the first 
new drug approved to treat this disease in over 14 years.  
Ipilimumab is a monoclonal antibody that sticks to an important 
protein on blood cells T-lymphocytes, the most important immune-
system cells in controlling tumor growth. Ipilimumab blocks a 
signal on T-cells that suppresses their activation after a normal, 
vigorous response to infection or inflammation. This suppression 
protects our tissues from being attacked by our own overactivated 
T-cells. But it can also prevent our T-cells from attacking tumor 
cells. Blocking the signal with ipilimumab allows T-cells to recover 
their activity and kill tumor cells (Fig. 5A). While ipilimumab can 
provide long-term remission (20% of the cases) (Schadendorf D., 
2015) for a fraction of patients, it occasionally causes dangerous 
side effects resulting from an autoimmune reaction in which the 
patient’s overstimulated immune system attacks not only cancer 
cells but the patient’s healthy tissues. 
 Drugs that Block PD-L1 or PD-1  
In 2015, the European Medicines Agency (EMA) approved 
OPDIVO
®
 (Nivolumab) and KEYTRUDA
®
 (Pembrolizumab) as 
drugs that block PD-L1 or PD-1 and tumor-infiltrating lymphocyte 
therapies. Melanoma cells often have a protein on their surface 
called PD-L1 that helps them evade the immune system (Fig. 5B).  
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The PD-L1 on tumor cells links to a receptor called PD-1 on T-
cells, causing the activation of their programmed cell death. This 
lethal phenomenon can be prevented by blocking the interaction 
between PD-L1 and PD-1. Blocking either PD-L1 or PD-1 can 
allow the T-cells to attack the tumor effectively. Antibodies that 
block PD-L1 or PD-1 may have higher antitumor activities than 
Ipilimumab (Weber JS., 2015). They also appear to be associated 
with milder and less frequent autoimmune complications. 
Combinations of ipilimumab and PD-1-blocking antibodies are 
being studied because their effects are slightly different, so together 
they may stimulate the immune system even more effectively than 
either drug alone. 
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Fig 5: Anti-PD1 and –CTLA-4 mechanisms of action 
(A) Adapted from Lesbo et al., ESMO 2008. (B) Adapted from 
http://www.nature.com/nature/journal/v515/n7528/images/515496a-f1.jpg  
Antigen-presenting cell (APC), Cytotoxic T-lymphocytes antigen-4 (CTLA-
4),  Major histocompatibility complex (MHC), T-cell receptor (TCR) 
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2. THE TUMOR MICROENVIRONMENT 
An important regulator of normal cell behavior and tissue 
homeostasis is the surrounding extracellular matrix (ECM). The 
ECM has many functions, including acting as a physical scaffold, 
thus facilitating interactions between different cell types and 
providing survival and differentiation signals. Maintaining organ 
homeostasis can prevent neoplastic transformation in normal tissues 
by ensuring stable tissue structure, mediated by tight junction 
proteins and cell adhesion molecules such as β1 integrins and 
epithelial (E)-cadherin (Nelson CM., 2006). However, the presence 
of transformed tumor cells initiates crucial changes that can convert 
this environment into one that supports cancer progression (Junttila 
MR., 2013). In fact, cancers are not just masses of malignant cells, 
but complex “organs” where many other cells are recruited to be 
corrupted by transformed cells. Interactions between malignant and 
non-transformed cells create the tumor microenvironment (TME) 
(Balkwill FR., 2012). The orchestration of these changes involves 
recruitment of fibroblasts, migration of immune cells, matrix 
remodeling and eventually development of vascular networks. 
Regional differences into the same tumor mass, such as hypoxia, 
acidity and the presence of growth factors, actively shape its 
development. A unique environment emerges in the course of tumor 
progression as a result of interactions between tumor and host. It is 
created and at all times shaped and dominated by the tumor, which 
orchestrates molecular and cellular events taking place in 
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surrounding tissues (Whiteside TL., 2008). The evolution, structure 
and activities of the cells in the TME have many parallels with the 
processes of wound healing and inflammation (Grivennikov SI., 
2010; Hanahan D., 2011; Mantovani A., 2008). 
Although the expansion of neoplastic cells generates the initial 
insult that instigates the creation of the tumour niche, non-
transformed cell types (Junttila MR., 2013) and protein 
compartment of the ECM (Balkwill FR., 2012) co-evolve with the 
tumor cells, so that both continuously participate in the process of 
tumorigenesis (Joyce JA., 2009).  
 
2.1. TUMOR MICROENVIRONMENT ARRANGEMENT 
Different stromal cell types have been recruited to the primary 
tumor site as endothelial cells, pericytes, fibroblasts and various 
bone marrow derived cells (BMDCs), including macrophages, 
neutrophils, mast cells, myeloid cell-derived suppressor cells 
(MDSCs) and mesenchymal stem cells (MSCs).  
 VASCULATURE 
Vascular networks are derived through formation of new vessels 
(angiogenesis), co-option and modification of existing vessels 
within tissues, or recruitment and differentiation of endothelial 
precursors from bone marrow (vasculogenesis), all of which 
contribute to vascular heterogeneity in and among tumors. Vessel 
formation involves degradation and reincorporation of existing 
vascular basement membranes that vary in a tissue-specific manner 
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(Kalluri R., 2003). Many soluble factors present in the TME, such 
as Vascular Endothelial Growth factors (VEGFs), Fibroblast 
Growth factors (FGFs), platelet-derived growth factors (PDGFs) 
and chemokines stimulate endothelial cells and their associated 
pericytes during the neovascularization (Carmeliet P., 2011). The 
organization of tumor vascularization is abnormal in almost every 
aspect of its organization and function (Jain RK., 2005): blood 
vessels are characterized by chaotic branching structures with 
irregular and permeable vessel lumen. The leakiness of the vessels 
raises the interstitial fluid pressure causing unevenness of blood 
flow, oxygenation, nutrient and drug distribution, thus increasing 
hypoxia and facilitating metastasis.  
Microvessel high density has been reported to be a significant 
prognostic factor for poor outcome in various carcinoma types as 
non-small-cell lung cancer (NSCLC) (Meert AP., 2002) colorectal 
(Des Guetz G., 2006) and breast cancers (Uzzan B., 2004). 
Moreover, elevated expression of the predominant pro-angiogenic 
ligand VEGF-A has been shown to be associated with a worse 
prognosis compared with cancer with low expression of VEGF-A in 
metastatic colorectal, lung and renal cell cancers (Hegde PS., 2013).  
 IMMUNE CELLS 
The immune system collectively functions to recognize and protect 
tissues from infections and damage. Both the innate and adaptive 
immune systems have been implicated in promoting and preventing 
tumor growth (Junttila MR., 2013). Tumor masses are generally 
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characterized by high heterogeneity of the tumor immune context, 
being influenced by various additional factors, as the extent and 
permeability of the vasculature, and by the actions of tumor cells 
themselves. Even within the same lesion, the distribution of 
immune cell infiltration is not uniform. In fact the presence of 
immune cells on the leading edge of the lesion has a different 
prognostic significance than in central areas, thus indicating the 
crucial nature of intratumoral localization (Fridman WH., 2012).  
 EXTRACELLULAR VESICLES 
In order to achieve these defining features of the tumor 
microenvironment, cancer and non cancer cells have to exchange 
continuously information. One way to sustain this “informational-
trafficking” is packaging different molecules into membrane-
enclosed vesicles widely known as extracellular vesicles (EVs). 
They contain cargos such as lipids, proteins, various RNAs and 
DNA fragments as well as metabolic products. These vesicles, with 
different subcellular origin, can shuttle these molecules between 
tumor cells and surrounding stroma inducing signaling pathway or 
directly altering their phenotype. One kind of EVs, so called 
exosomes (50-150 nm), origins in secretory multi-vesicular bodies 
that fuse with the cellular membrane releasing intraluminal vesicles 
(Wendler F., 2016; Felicetti F., 2016). They have been recently 
implicated as direct mediators of the response of solid tumors to 
cytotoxic chemotherapy and as putative “real-time” circulating 
biomarkers; finally circulating EVs can also transport important 
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molecules to remote destinations in order to lead metastatic 
properties in other healthy tissues (Felicetti F., 2016) (Fig. 6).  
 
 
 
 
 
 
2.2. ECM 
The ECM provides not only a physical scaffold for all cells in the 
TME, but also has a dynamic role in the evolution and spread of 
cancers, especially considering that cell adhesion to the ECM is a 
key step for its movement out of and into the TME. The ECM also 
contains fundamental growth factors, such as angiogenic factors and 
chemokines, which interact with cell surface receptors giving to 
each tissue its tensile and compressive strength and elasticity 
(Frantz C., 2010). Tumors are typically stiffer than the surrounding 
Fig 6: Tumor microenvironment cells component  
(Daniela F Quail and Johanna A Joyce, Microenvironmental regulation of 
tumor progression and metastasis. Nat. Med. 2013).  
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normal tissues owing to an increased ECM deposition by CAFs 
(cancer–associated fibroblasts) (Weigelt B., 2008). Collagen and 
elastin fibers are reorientated and cross-linked by lysyl oxidase 
(LOX) and transglutaminase present in the TME, resulting in larger, 
more rigid fibrils (Levental KR., 2009). Matrix metalloproteases 
(MMPs), that degrade ECM proteins, are secreted and activated by 
malignant cells, Tumor-associated macrophages (TAMs) and CAFs. 
MMPs further remodel the ECM, thereby releasing chemokines, 
growth and angiogenic factors. Other proteases that are upregulated 
in the cells of the TME include a large family of cysteine proteases, 
the cathepsins. Cathepsin L, for instance, processes and activates 
heparanase, thereby aiding metastasis, angiogenesis and 
inflammation (Edovitsky E., 2004; Lerner I., 2011). In addition 
diverse group of matricellular proteins includes the glycoproteins 
secreted protein acidic and rich in cysteine 
(SPARC/osteonectin/BM40), thrombospondin (TSP), tenascin C 
(TNC), osteopontin (OPN) and periostin (POSTN) (Bornstein P., 
2002).  
 
2.2.1. SPARC IN CANCER: A FOCUS ON MELANOMA 
MODEL 
SPARC is an extracellular matrix-associated glycoprotein first 
identified by Termine and coworkers as a major non-collagenous 
constituent of bovine bone (Termine JD., 1981). SPARC is a single-
copy gene with a high degree of evolutionary conservation. The 
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human gene has been localized to chromosome 5q31-33, whereas 
the murine homolog is in the central region of chromosome 11. The 
vertebrate SPARC gene encodes proteins of 298-304 amino acids, 
whose initial 17 aa constitute a signal sequence that is removed 
prior to secretion of the protein. SPARC protein structure is 
organized in three different domains: the NH2-acidic region, the 
follistatin-like domain and the COOH-extracellular Ca
2+ 
region.  
The role of SPARC in tissue homeostasis is exemplified by the 
phenotypes of SPARC-deficient mice characterized by cataract 
formation and osteopenia, decreased size and tensile strength of 
dermal collagen fibers, and increased deposition of adipose tissue 
(Chavey C., 2006; Nie J., 2009). Reported phenotypes were related 
to defects of fibroblast differentiation and plasticity and increased 
leukocyte recruitment (Bradshaw AD., 2009; Chiodoni C., 2010, 
Rentz TJ., 2007; Sangaletti S., 2011). SPARC role in carcinogenesis 
is particular interestingly as it plays multi-faceted contextual roles 
depending on the tumor type and on its origin, being either 
produced by cancer or surrounding stromal cells (Said N., 2005; 
Said N., 2013; Said N., 2009) 
In melanoma, SPARC expression has been reported to increase with 
tumor progression, and its expression shown to be a marker of poor 
prognosis (Girotti MR., 2011). Accordingly SPARC knockdown in 
melanoma cells lead to the complete loss of their in vivo 
tumorigenic growth in nude mice (Ledda MF., 1997) through a 
mechanism involving the activation of polymorphonuclear cell anti-
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tumor activity. Importantly, SPARC expression in melanoma cells 
has been associated with the acquisition of mesenchymal 
characteristics with reduced E-cadherin expression (Robert G., 
2006). However, the in vivo tumorigenicity and invasiveness of 
melanoma cells injected in nude mice were dependent on SPARC 
released by tumor cell, but not by fibroblasts (Alvarez MJ., 2005; 
Prada F., 2007).  
 
2.3. LIPID ROLE IN TUMOR FORMATION AND 
PROGRESSION 
Hallmarks of cancer comprise six biological capabilities acquired 
during the multistep development of human tumors. These 
hallmarks constitute an organizing principle for rationalizing the 
complexities of neoplastic disease. They include sustaining 
proliferative signaling, evading growth suppressors, resisting cell 
death, enabling replicative immortality, inducing angiogenesis, and 
activating invasion and metastasis. The origins of these hallmarks 
are genome instability, which generates the genetic diversity that 
expedites the acquisition of these properties, and inflammation, 
which fosters multiple hallmark functions. Recent data in the last 
decade has evidenced two emerging hallmarks of tumor formation 
and progression, such as reprogramming of energy metabolism and 
evading immune system activation (Fig. 7) (Hanahan D., 2011).  
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Today the central role played by bioactive lipids and fatty acids 
(FAs) as mediators of the crosstalk between cancer cells and stroma 
has been clearly recognized (Beloribi-Djefaflia S., 2016).  
The required changes in metabolic activity are driven by oncogenic 
signals and by the particular organization of the surrounding stroma, 
which is characterized by poor oxygenation and nutrient scarcity. 
As a result tumor cells are forced to modify their metabolic balance 
to overcome this hostile microenvironment. One of the first events 
in tumor cells metabolism is an alteration on glucose metabolism, 
known as “Warburg effect” (Warburg O., 1956). Besides these 
Fig 7: Hallmarks of Cancer: The Next Generation  
(Adapted from Hanahan D and Weinberg RA, Cell 2011)  
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events, cancer cells show a strong lipid and cholesterol avidity in 
order to sustain their highly proliferative rate (Zaidi N., 2013). 
Lipid synthesis describes the processes that convert nutrient derived 
carbons into FAs. The first step involved in FA and cholesterol 
biosynthesis is the production of two-carbon units in the form of 
acetyl-CoA. Acetyl-CoA is generated from citrate by the enzyme 
ATP-citrate lyase (ACLY) and then converted to malonyl-CoA by 
the enzyme acetyl-CoA carboxylase (ACC). Acetyl-CoA and 
malonyl-CoA are then coupled to the acyl-carrier protein domain of 
the multifunctional enzyme fatty acid synthase (FASN). Repeated 
condensations of acetyl groups generate a basic 16-carbon saturated 
FA, named palmitic acid (C16:0). Palmitic acid is further elongated 
and desaturated to generate the diverse spectrum of saturated and 
unsaturated FAs synthesized by mammalian cells, as stearic acid 
(C18:0). One of the main desaturases in mammalian cells are the 
stearoyl CoA desaturases (SCDs), integral endoplasmic reticulum 
proteins that catalyse the introduction of the first double bond in the 
cis-Δ9-position to convert saturated FAs (SFAs), palmitic and 
stearic acid, into mono-unsaturated FAs (MUFAs), palmitoleic acid 
(C16:1) and oleic acid (C18:1) respectively (Ntambi JM., 2004).  
There are two isoforms in humans, SCD1 (also named SCD) 
(Whang J., 2005), which is highly expressed in adipose tissues, as 
well as in brain, liver, heart and lung, and SCD5, which is expressed 
in few normal tissues (brain, pancreas), playing physiological and 
pathological functions virtually unknown (Igal RA., 2010). In 
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contrast, the murine genome encodes four SCD (SCD1-4) enzymes 
with partially overlapping functions. SCD1 was found to be 
overexpressed in tumors from several cancer types, including 
prostate (Fritz V., 2010), liver (Huang GM., 2015), kidney (Von 
Roemeling CA., 2013) and breast cancer, where it correlates with 
reduced survival (Holder AM., 2013). Antisense-mediated 
downregulation of SCD expression was found to inhibit 
proliferation and tumor formation in human lung cancer cell lines 
(Scaglia N., 2008), thus leading to cell cycle arrest and apoptosis 
(Hess D., 2010). Further evidence that lipid desaturation is an 
important metabolic process in tumors is provided by investigating 
the composition of membrane lipids in human breast cancer 
samples. Tumor tissues showed an overall increased amount of 
membrane phospholipids, sphingomyelins and ceramides, while 
triacylglycerides were unchanged. Interestingly, the most prominent 
changes were seen in triple negative breast cancers, the most 
aggressive form of the disease. In contrast to normal breast tissue, 
lipids from the tumor samples contained a higher proportion of 
saturated and mono-unsaturated acyl chains, which are indicative of 
increased reliance on de novo synthesis rather than uptake of dietary 
lipids, which contain a higher proportion of poly-unsaturated FAs 
(Hilvo M., 2011).  
In particular oleic acid (OA) has attracted much attention, especially 
in the last years, as the “Mediterranean diet”, characterized by high 
olive oil consumption (rich in OA), has been traditionally linked to 
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a protective effect against cancer (Trichopoulou A., 2000). A wide 
range of studies have been conducted into breast cancer, where the 
potential protective effect of olive oil and OA has been clearly 
demonstrated (Chajes V., 2008). In addition, epidemiological 
studies suggest that olive oil may have a protective effect on 
colorectal cancer development (Bautista D., 1997; Stoneham M., 
2000). Some animal studies have also shown that dietary olive oil 
prevented the development of colon carcinomas also in rat models 
corroborating the idea that olive oil may have chemopreventive 
properties against colon carcinogenesis (Bartoli R., 2000).  
Membrane Lipid Therapy (MLT) is a novel therapeutic approach in 
which the drugs are designed to target the membrane of tumor cells, 
modulating its composition and structure and therefore modifying 
the activity of membrane-interacting protein. (Llado V., 2014).  
Minerval (2-hydroxyoleic acid, 2-OHOA) is an orally bioavailable 
synthetic analog of the oleic acid that selectively modulates 
sphingomyelin synthase (SMS) activity, thereby increasing the 
concentration of sphingomyelin (SM), ceramide (Cer) and 
diacylglycerol (DAG) in the tumor cell membranes and decreasing 
the levels of phosphatidylethanolamine (PE), phosphatidylcholine 
(PC) and phosphatidylserine (PS). This treatment restores the 
normal, healthy levels and ratios of membrane lipids, inhibiting 
membrane-protein associated signaling and the aberrant activity of 
signaling pathways in tumor cells, including the RAS/MAPK and 
PI3K/AKT pathways, stopping tumor cell proliferation, inducing 
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tumor cell differentiation and eventually causing selective cancer 
cell death by autophagy/apoptosis (J Martinez 2005). Minerval 
exhibits a wide range of action, inhibiting the proliferation rate in 
various human carcinoma cells, especially lung and glioma 
(Martinez J.,  2005; Llado V., 2010; Barceló-Coblijn G., 2011; 
Terès S., 2012, Terès S., 2012, Marcilla-Etxenike A., 2012). The 
European Medicines Agency (EMA) designated 2-OHOA as an 
orphan medicinal product for the treatment of glioma in October 
2011 (http://www.ema.europa.eu).  
A novel approach to chemotherapy has the potential to yield novel 
dietary-drug combinations that can provide additive or even 
synergistic protection against the progression of cancer. With regard 
to this novel approach, OA has been reported to act synergistically 
with cytotoxic drugs, thus enhancing their antitumor effect 
(Menéndez JA., 2001).  
Recently Sujin Jung and colleagues manufactured an alternative 
complex using liposome as an oleic acid delivery vesicle, called this 
nano-lipo-complex LIMLET (LIposome Made LEthal to Tumor 
cell). They tested its cytotoxicity against two cancer cell lines, 
MDA-MB-231 (human breast cancer) and A549 (human lung 
cancer), demonstrated that LIMLET showed distinctive cytotoxicity 
against A549 and MDA-MB-231 cells. Conversely, empty-
liposomes (containing no oleic acid) had no toxicity, even at high 
concentrations. Also this lipo-complex demonstrated selective, 
concentration-dependent toxicity against these cancer cells (Jung S., 
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2016). Little is known about the molecular mechanisms basing the 
antitumor effects of oleic acid. Key studies evaluating these are 
summarized below (Fg. 8).  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Fig 8: Antitumoral roles of Oleic Acid  
(inspired from  Carrillo C.  Nutr. Hosp., 2012  
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3. MicroRNAs 
Multiple types of small RNAs have evolved in eukaryotes to 
regulate genetic material and transcripts. These small RNAs are 
classified in three different family in animal: microRNA (miRNA), 
siRNA and PIWI-interacting RNA (piRNA).  
At present microRNAs represent the dominant class of small RNAs 
in most somatic tissues, functioning as guide molecules in RNA 
post-trancriptional regulation. Targeting most protein-coding 
transcripts these molecules are involved in all developmental an 
pathological processes. Mature miRNAs produced by two RNaseIII 
protein, Drosha and Dicer are 21-25 nucleotides in length.  
Repression is obtained by miRNA base pairing with mRNA targets 
in presence of the effector protein AGO. This protein functions by 
recruiting factors that induce translational repression, mRNA 
deadenylation and mRNA decay (Huntzinger E., 2011). Binding 
sites for miRNAs are usually, but not always, located in the 3ʹ 
untranslated region (UTR) of mRNAs (Bartel DP., 2009). More 
than 60% of human protein-coding genes contain at least one 
conserved miRNA-binding site and, considering that numerous non-
conserved sites also exist, most, if not all, protein-coding genes may 
be under the control of miRNAs (Friedman RC., 2009). Thus, it is 
not surprising that the biogenesis and function of miRNAs 
themselves are tightly regulated, and that their dysregulation is 
often associated with human diseases, including cancer (Lujambio 
A., 2012) and neurodevelopmental disorders (Im HI., 2012).  
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3.1. MicroRNAs BIOGENESIS 
MiRNA genes are transcribed by RNA polymerase II and their 
sequences are located within various genomic contexts. In humans, 
the majority of canonical miRNAs are encoded by introns of non-
coding or coding transcripts, and few miRNAs by exonic regions. 
Often, several miRNA loci are in close proximity to each other, 
constituting a poly-cistronic transcription unit (Lee Y., 2002). In 
general, miRNAs belonging to the same genetical cluster are co-
transcribed, but each single microRNA can be additionally 
regulated at post-transcriptional level. Following transcription, the 
primary miRNAs (pri-miRNA) are submitted to several step of 
maturation (Lee Y., 2002), typically long over 1kb. The nuclear 
RNase III Drosha and the cofactor DGCR8 initiate the maturation 
process by cropping the stem–loop, contained into the pri-miRNAs, 
to release a small hairpin-shaped RNA of 70-100 nucleotides in 
length (pre-miRNA) (van Rooij E., 2011). Following Drosha 
processing, pre-miRNAs ar exported into the cytoplasm, where 
maturation can be completed. The protein exportin 5 (EXP5), 
encoded by XPO5 gene, forms a transport complex with the GTP-
binding nuclear protein RAN-GTP and the pre-miRNA (Lund E., 
2004). Following translocation through the nuclear pore complex, 
GTP is hydrolyzed, resulting in the disassembly of the complex and 
pre-miRNA release into the cytosol, where is cleaved by Dicer near 
the terminal loop. A small RNA duplex, preferentially loaded into 
AGO protein, is then delivered to form an effector complex called 
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RNA-induced silencing complex (RISC) (Bernstein E., 2001; 
Hammond SM., 2001) which quickly removes the passenger strand 
to release the mature miRNA (Fig. 9).  
 
 
 
 
 
3.2. MicroRNA-221/-222 IN MELANOMA 
MiR-221 and -222 are co-transcribed in a common RNA precursor, 
localized on chromosome X. In addition they share the same seed 
sequence. Both these characteristics suggest that these two miRs 
play common functions. Deregulated expression of miR221/-222 
has been detected in many different cancers (Ciafrè SA., 2005; 
Fig 9: miRNAs biogenesis  
(Adapted from Winter J. Nat. Cell. Biol, 2009)  
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Visone R., 2007; Garofalo M., 2009; Miller Te., 2008; Medina R., 
2008; Felicetti F., 2008) where they are mostly upregulated.  
Specifically, Felicetti and co-workers reported miR221/-222 
increasingly expressed during the multistep process from normal 
melanocytes to advanced metastatic melanomas (Felicetti F., 2008). 
To demonstrate their functional role, miR221/-222 have been 
overexpressed in a moderately aggressive melanoma cell line, 
selected for its low levels of endogenous miR221/-222 and for its 
ability to produce melanin. As a direct effect, the enforced miR-221 
and miR-222 expression resulted in significant increases of the 
proliferative growth rate, the invasive and chemotactic capabilities, 
as well as of the anchorage-independent growth. Their tumorigenic 
function was also confirmed in an in vivo model where miR-
221&222 overexpression increased tumor volumes of mice 
subcutaneously injected with miR-221&222-transduced melanoma 
cells compared with controls. More important was the opposite 
effects obtained by silencing of miR221/-222 in metastatic cells, 
where transfection of chemically modified oligomers (antagomirs) 
inhibited the main functional properties associated with advanced 
melanoma.  
MiR221/-222 exert their function by repressing a number of 
antineoplastic genes. In particular in melanoma they inhibit p27
Kip1
 
and c-KIT receptor, thus promoting cell proliferation and 
differentiation blockade (Felicetti F., 2008; Igoucheva O., 2009). 
p27
Kip1
 is a cell-cycle regulatory protein that interacts with cyclin-
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CDK2 and -CDK4, blocking cell cycle progression at the G1/S 
checkpoint. Regulation of p27
Kip1
 by miR-221 and miR-222 
represents an additional oncogenic mechanism underlying the 
abnormal cell cycle rate of advanced melanoma and of many other 
tumors (Medina R., 2008; Felicetti F., 2008). MiR221/-222 
inhibitory effect on melanogenesis is exerted by repressing the c-
KIT tyrosine kinase receptor (Felicetti F., 2008). The stem cell 
factor (SCF)/c-KIT signaling pathway is essential during 
melanocytes migration from the neural crest to the skin and it plays 
an important role in melanogenesis, cell growth, migration, and 
survival (Alexeev V., 2006). While ubiquitously expressed in 
mature melanocytes, c-KIT is downregulated in up to 70% of 
metastases, allowing melanoma cells to escape SCF/c-KIT–
triggered apoptosis (Willmore-Payne C., 2005). The transduction 
signal generated by SCF/c-KIT interaction induces the activation of 
Microphthalmia-associated transcription factor (MITF) protein, 
known to regulate a broad repertoire of genes whose functions in 
melanocytes include development, differentiation, survival, cell-
cycle regulation and pigment production. In particular, MITF 
controls the melanin production directly regulating the main 
melanogenic enzymes, such as tyrosinase (TYR) and tyrosinase-
related protein 1 (TYRP1). Reported results showed that, as a 
consequence of the miR-221&222-dependent suppression of c-KIT, 
the downstream MAPK signaling cascade is also affected in turn 
resulting in a moderate downregulation of MITF, TYR and TRP-1 
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(Fig. 10).  
 
 
 
 
In accordance, miR221/-222 overexpression in a primary melanoma 
cell line caused reduction of both differentiation and melanogenesis, 
as hallmarks of an oncogenic progression (Felicetti F., 2008). The 
regulation of MITF expression in melanoma cells appears extremely 
complex as, according to a proposed model, MITF high levels result 
in cell cycle arrest and differentiation, intermediate levels promote 
proliferation and tumorigenesis, whereas low amounts lead to cell 
cycle arrest and apoptosis (Wellbrock C., 2005; Goding C., 2006; 
Gray-Shopfer V., 2007; Hoek KS., 2010).  
 
Fig. 10: melanogenesis pathway 
In response to the activation of c-KIT signaling, MITF is phosphorylated 
by MAPK and translocated from the cytoplasm in the nucleus to activate 
transcription of melanogenic genes.  
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3.2.1 REGULATION OF MicroRNA-221/-222 TRANSCRIPTION  
Among diverse miRs, particular attention has been paid on the 
transcriptional regulation of miR221/-222 in different types of 
cancers, including melanoma, where different groups evidenced 
both positive and negative regulators of transcription (Garofalo M., 
2012) 
Their regulatory binding sites have been identified in the putative 
promoter region upstream to pre-miR-222 between -400 and -50 bp 
(Felicetti F., 2008; Di Leva G., 2010; Mattia G., 2011). Felicetti and 
colleagues highlighted the first negative regulation system of 
miR221/-222 transcription played by the Promyelocytic Leukemia 
Zinc Finger (PLZF) transcription factor in melanoma cell lines. 
PLZF is a tumor suppressor gene, barely or not detectable in 
melanomas, but expressed in normal melanocytes. Two putative 
consensus binding sequences for PLZF are located upstream to 
premiR-222 and a third site is localized in the intragenic region 
between the two miR sequences. In advanced melanomas the lack 
of PLZF allows miR-221/222 up-modulation and, in turn, the 
activation of two oncogenic pathways involved in melanoma 
progression, through p27Kip1 and c-KIT deregulation (Felicetti F., 
2008) (Fig. 11 A-B).  
A more complex function played by ETS-1 transcription factor on 
miR221/-222 regulation was demonstrated in melanoma (Mattia G., 
2011). ETS-1 transcription factor is the founding member of the 
ETS gene superfamily, encoding a class of phosphoproteins 
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characterized by a conserved domain that recognizes and binds to a 
GGAA⁄ T DNA core sequence. The complexity of ETS-1 action has 
been well demonstrated by the authors that discover its capability of 
either negative or positive regulation on miR221/-222 transcription, 
in early and advanced melanoma cells, respectively. ETS-1 post-
translational modifications, rather than its total protein content, look 
functionally relevant to melanoma. In fact, a key role is associated 
with the status (phosphorylated or not) of Thr38. In low grade 
malignant cells the presence of significant amounts of barely or not 
phosphorylated ETS-1 negatively act on miR-221/222 transcription. 
Conversely, in metastatic melanomas the persistent activation of the 
MAPK-ERK1⁄2 cascade increases the fraction of Thr38 
phosphorylated ETS-1 inducing miR221/-222 transcription and 
possibly tumor malignancy (Mattia G., 2011) (Fig. 11 A-B).  
Errico and colleagues demonstrated that the HOXB7/PBX2 dimer 
acts as a positive transcriptional regulator of the oncogenic 
microRNA221/-222. In addition, demonstrating c-FOS as a direct 
target of miR-221&222, they identified a HOXB7/PBX2 miR-
221&222 c-FOS regulatory link, whereby the abrogation of 
functional HOXB7/PBX2 dimers leads to reduced miR-221&222 
transcription and elevated c-FOS expression with consequent cell 
death. Taking advantage of the treatment with the peptide HXR9, an 
antagonist of HOX/PBX dimerization, they recognized miR-
221&222 as effectors of its action, in turn confirming the HXR9 
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efficacy in the treatment of human melanoma malignancy, whilst 
sparing normal human melanocytes (Errico MC., 2013).  
More recently Felli and co-workers demonstrate the circuitry 
connecting the oncomiR221/-222 with the tumor suppressors miR-
126/-126* in melanoma development and progression. Accordingly 
to the inverse correlation between endogenous levels of miR221/-
222 and miR-126/-126*, respectively increasing or decreasing with 
malignancy and looking for a central player in this complex 
network, they revealed the regulation role of AP2α, which is on one 
side directly targeted by miR221/-222 and on the other 
transcriptional activator of miR-126/-126* (Felli N., 2013). These 
authors showed the chance of restoring miR-126&126* expression 
in metastatic melanoma to control miR-221&222 levels. Thus, the 
low-residual quantity of miR-221&222 should assure the release of 
AP2α expression, which in turn can bind to miR-126&126* 
inducing their transcription. All together these results point to an 
unbalanced ratio functional to melanoma malignancy between these 
two couples of miRs (Felli N., 2015) (Fig. 11 A-B).  
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Fig 11: Regulation of miR221/-222 transcription 
(A) Neoplastic pathway. (B) Normal or therapeutic pathway  
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AIMS OF THE STUDY 
Melanoma is one of the deadliest skin cancers and its incidence is 
rapidly increasing in the world. Surgical resection is curative only at 
early stages, but new efforts are needed to contrast the 
metastatization phase (survival rates 6-8% at 5 years with a median 
survival of 6-9 months). Thus, the investigation of new therapeutic 
options must be contextual to the progress of the melanoma biology 
understandings. Different questions continue to be obscure starting 
from the high heterogeneity of this tumor and the different 
metabolic options of melanoma cells that consent them to adapt to 
and modify the microenvironment, eventually using it for 
metastatization. In fact, metabolic pathways substantially contribute 
to human cancer and growing evidences are associating lipids with 
tumor development and, above all, its progression.  
The aim of this study was to reveal the function of the SCD5 Δ9-
desaturase enzyme, and eventually of its main biological product 
oleic acid (OA), in cancer being its pathophysiological role 
essentially unknown. 
We looked at SCD5 role in human melanoma cells, evaluating 
whether the SCD5-dependent new balance of fatty acids 
(specifically oleic and stearic acids) could have any effect on tumor 
progression. In addition, as a second model, we utilized the murine 
4T1 mammary carcinoma cell line, as a suitable model for studying 
spontaneous metastases in vivo in syngeneic mouse models.  
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RESULTS 
4. EXPRESSION ANALYSIS OF STEAROYL-COA Δ9 (SCD5) 
DESATURASE IN MELANOMA.  
In view of the increasing role acquired by lipid metabolism in tumor 
initiation and progression, we focused our study on the role of 
SCD5 desaturase in melanoma being intrigued by its virtually 
unknown role in cancer (Igal RA., 2010).  We have evaluated by 
qRT-PCR and/or western blot analyses the expression of SCD5 
isoenzyme in normal human epidermal melanocytes (NHEM) from 
foreskin and in some representative melanoma cell lines derived 
from tumors at different stages of progression (Fig. 12 A-B).  
The expression of SCD5, that was barely detectable in normal 
melanocytes, resulted significantly higher in primary melanoma cell 
lines than in metastatic cells, at both mRNA and protein levels.  
To confirm the expression pattern of SCD5 observed in melanoma 
cell lines we decided to run parallel analyses on a series of human 
bioptic speciments from primary and metastatic melanoma, by 
using an immunohistochemical approach. Results showed a sharp 
positivity in primary cutaneous melanomas, whereas SCD5 was 
virtually absent in the metastatic ones, corroborating the expression 
data obtained in melanoma cell lines (Fig. 12 C).  
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Knowing the biochemical role of SCD enzymes in introducing the 
first double bond in cis Δ9 position of SFAs (palmitic and stearic 
acid) to produce MUFAs (mainly palmitoleic and oleic acid, 
respectively) (Ntambi KM., 2004) (Fig. 13 A), we evaluated by gas 
chromatography/mass spectrometry (GM/MS) analyses the 
enzymatic activity of SCD5 on cell lysates from normal human 
melanocytes as well as from some representative differently staged 
melanoma cell lines. Interestingly, a close correlation between 
Fig 12: SCD5 endogenous expression levels in differently tumor staged 
melanoma samples.   
Endogenous levels of SCD5 were evaluated in differently staged melanoma 
cell lines and normal human epidermal  melanocytes (NHEM) by (A) qRT-
PCR and (B) western blot analyses  (mean ±  SD of at least three independent 
analyses).  (C) Immunolocalization of SCD5 in primary cutaneous and 
metastatic human melanoma specimes,  representative sections are shown 
(magnification=10X).  
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SCD5 downregulation and the decreased amount of oleic acid 
occurring in the more aggressive melanomas was detected, 
suggesting that SCD5 restored expression or oleic acid 
supplementation might antagonize the aggressiveness of advanced 
melanoma (Fig. 13 B). 
 
 
 
 
 
 
 
5. REGULATION OF SCD5 EXPRESSION IN MELANOMA.  
Our study on Δ9-Stearoyl CoA desaturase 5 showed that its 
expression was significantly higher in primary than in metastatic 
Fig 13: SCD5 biochemical role and oleic acid content in melanoma 
progression.  
(A) Schematic depiction of the SCD5-dependent conversion of saturated 
fatty acid (FAs) into mono unsaturated fatty acids (MUFAs). (B) GC/MS 
based quantification of endogenously produced oleic acid at different 
stages of melanoma progression. Representative  experiments are shown 
and levels of oleic acid are indicated as fold changes compared to normal 
human epidermal melanocytes (NHEM). 
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melanoma, being barely or not detectable in normal melanocytes 
(Fig. 12 A-B) (Bellenghi M., 2015). 
Following the idea that SCD5 carries tumor suppressor gene 
functions, we investigated the possible regulatory mechanisms 
underlying SCD5 reduction during melanoma progression, looking 
for i) the option of epigenetic mechanisms; ii) different 
mRNA/protein stabilities of SCD5, possibly associated with tumor 
advanced phases iii) possible miR-dependent SCD5 post-
transcriptional regulation.  
 
5.1. SCD5 EPIGENETIC REGULATION.  
Literature data evidenced lots of tumor suppressor genes 
epigenetically inactivated by DNA methylation and/or histone 
modification, as Retinoblastoma 1 (Rb1), tumour protein p53 
(TP53), Wilms tumour 1 (WT1), neurofibromin 1/2 (NF1/2), von 
Hippel-Lindau tumour suppressor (VHL), adenomatous polyposis  
coli (APC), cyclin-dependent kinase inhibitor 2A (CDKN2A) 
(Feinberg AP., 2016).  
The UCSC Genome Browser (https://www.genome.ucsc.edu/cgi-
bin/hgGateway) indicates the presence of CpG islands (CpG island 
n°118) in SCD5 promoter (Chr4: 83719009-83720241), showing 
the option of promoter methylation.  
Epigenetic analyses were conducted by using 5-aza-2'-
deoxycytidine (5AzaCdR), a derivative of the most popular 
inhibitor of DNA (Cytosine-5-)-Methyltransferase 1 (DNMT1), 
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which is incorporated into DNA during the S-phase of the cell cycle 
(Egger G., 2004). In parallel experiments we utilized Trichostatin A 
(TSA), an organic compound that selectively inhibits the class I and 
II mammalian histone deacetylases (HDACs) families of enzymes.  
To assess the possible SCD5 epigenetic regulation we selected 
Me1007 primary and A375M metastatic melanoma cell lines in 
view of their different SCD5 expression levels. SCD5 was re-
expressed in A375M advanced melanoma by 5AzaCdR treatment, 
indicating that at least in part SCD5 undergoes promoter 
methylation regulation. By contrast no striking effects seemed 
related with deacetylation. As expected no significant effects were 
produced in Me1007 early primary melanoma cell line neither with 
5AzaCdR nor with TSA treatments (Fig. 14 A-B), confirming the 
suggestion that SCD5 might be inactivated in aggressive melanoma 
in view of its antimetastatic role.  
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5.2. SCD5 mRNA AND PROTEIN STABILITIES.  
In order to check for the possibility of SCD5 different 
mRNA/protein stabilities along with tumor progression, we selected 
again Me1007, as a representative of primary melanoma and A375 
cells, instead of A375M previously analyzed, as a metastatic cell 
Fig 14: SCD5 epigenetic regulation 
Representative western blot analyses of SCD5 epigenetic regulation in (A) 
Me1007 primary melanoma cell line, which evidenced no significant effects 
with either 5AzaCdR or TSA treatments and (B) A375M metastatic melanoma 
cells, which  confirmed SCD5 CpG island promoter methylation, as evidenced 
by SCD5 induction upon 5AzaCdR treatment. P21 induction was used as 
positive control of treatment effectiveness. 
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line model. This choice because A375M cells, being totally 
negative for SCD5, are unsuitable for these kind of analyses. 
Firstly, we evaluated the mRNA stability by treating both 
melanoma cell lines with Actinomycin D [2µg/mL], which 
intercalates into DNA thus preventing RNA polymerase I activity. 
Although basal levels of SCD5 mRNA were obviously different, 
according to their diverse tumor stages (Fig. 12 A), we did not 
observe significant modifications in their degradation rates (Fig. 
15).  
 
 
 
 
In the same cell lines SCD5 protein degradation was then evaluated 
treating them with the protein synthesis inhibitor Cycloheximide 
(CHX) [50ɣ/mL]. Interestingly, the immunoblot analyses evidenced 
significantly accelerated protein degradation in the metastatic A375 
cell line (half-life ≈ 90 min), compared with the slower rate in 
Me1007 primary melanoma (half-life ≈ 12-hours) (Fig. 16 A). We 
Fig 15: SCD5 mRNA stability 
To evaluate SCD5 mRNA stability, Me1007 primary and A375 metastatic 
melanoma cell lines were treated with Actinomycin D. No significant 
differences were detected in their mRNA degradation  rates. 
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then verified whether the SCD5 different protein half-lives in 
primary and metastatic melanoma cell lines were depended on a 
different degradation rate regulated by the proteasome. Notably, 
treatment with proteasome inhibitor MG132 [10μM] blocked SCD5 
degradation in A375 cells, while it did not seem to affect the protein 
levels in Me1007, at least up to 15 hours (Fig. 16 B). Essentially, 
we detected a significantly more stable SCD5 protein in primary 
compared to metastatic melanoma cell lines, according to the 
expression pattern detected in our panel of cell lines (Fig. 12 A-B).  
 
 
 
 
 
 
 
 
 
 
 Results  
61 
 
 
 
 
 
 
 
 
5.3. SCD5miRs-REGULATORY SYSTEM.  
Considering the inverse relation between SCD5 and miR221/-222 
expression patterns, the first decreasing and the latter raising during 
melanoma progression (Fig. 17 A-B), and the presence of one 
conserved binding site for miR221/-222 in the 3’ Untranslated 
Fig 16: Evaluation of SCD5 protein stability and degradation 
Me1007 primary (A) and A375 metastatic (B) cell lines were treated 
with Cycloheximide  (CHX). In all the experiments protein extracts were 
subjected to western blotting analysis to detect SCD5 at the indicated 
time points. Results show a significative longer half-life of SCD5 protein 
in Me1007 compared with A375 cell line. The amounts  of SCD5, 
normalized on Tubulin constant levels, were plotted as a regression 
curve. (C, D) Western blot analyses show SCD5 accumulation in A375 
compared to Me1007 cell lines after MG132 treatment.  
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Regione (3’UTR) of SCD5 mRNA (http://www.targetscan.com), 
we hypothesized the involvement of these couple of miRs in SCD5 
regulation.  
 
 
 
 
 
 
Fig 17: Inverse correlation between SCD5 and miR-221/-222: in-vitro and 
in-vivo studies 
(A) Densitometric analysis of SCD5 protein and miR-221/-222 levels in 
normal melanocytes (NHEM) and representative differently staged melanoma 
cell lines. (B) In situ hybridization of miR-221/-222 and 
immunohistochemistry of SCD5. Bar, 50 μm. Representative sections from 
two primary and two metastatic human melanoma specimens are shown. 
Scrambled and RNU6B correspond to negative and positive controls, 
respectively.  
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To assess the possible miRs-dependent SCD5 regulation we used 
two different experimental sets: on the one side we utilized Me1007 
primary and A375M metastatic melanoma cell lines for their 
opposite expression level of SCD5. In fact Me1007 cells, positive 
for SCD5 and almost negative for miR221/-222, were lentivirally 
transduced with these two miRs, while A375M, negative for SCD5 
but highly expressing miR221-222, were transfected by antagomiRs 
to block miR221/-222 action. As expected for a miRs-dependent 
regulatory system, SCD5 protein expression was confirmed to be 
inversely related to miR221/-222 levels. Western blot analyses 
showed two opposite expression patterns: a significant miRs-based 
SCD5 downregulation in Me1007/miR-221 or miR-222 primary 
melanoma cells and its induction when miR-221 and/or -222 were 
abrogated after antagomir treatment in A375M metastatic cells (Fig. 
18 A-B). To verify the functional binding of miR221/-222 to the 
putative conserved site present in the 3′UTR of SCD5, we 
performed a series of luciferase assays. The SCD5 3’UTR, 
containing either the wild-type or mutated miR221/-222 binding site 
(Fig 18 C) was cloned downstream to the Renilla open reading 
frame in a modified psi-Check vector. Constructs were 
cotransfected into the 293FT cell line with miR221 and/or miR222, 
or with a non-targeting oligonucleotide as negative control. Results 
showed a significant miR221/-222 dependent inhibition of the 
Renilla activity (~50% reduction in 293FT in presence of both 
miRs). Importantly, mutation of nucleotides in the seed sequence 
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totally abrogated miR221/-222-dependent repression of Renilla in 
both cell lines (Fig. 18 D). All together these experiments 
demonstrate that miR221/-222 directly interact with and repress 
SCD5, probably suggesting a coordinated function of these couple 
of miRs in SCD5 post transcriptional regulation.  
 
 
 
 
6.4. SCD5 enforced expression favors melanoma differentiation 
through the up-modulation of MITF and the downmodulation of 
miR221/-222.  
Fig 18: miR-221&222 targeting of SCD5 
 (A) Representative WB analyses of SCD5 in (A) Me1007 control (Tween 
empty-vector) and miR221/-222-transduced cells, and (B) in antagomir-
221&222-transfected A375M cells. Tubulin was used as loading control. (C) 
Nucleotide pairing between SCD5 3′UTR and miR-221 and -222 sequences. 
The seed sequence is indicated in bold (red), while lower case letters with 
asterisks represent the mutated nucleotides. (D) Luciferase reporter assay 
performed in 293FT cell line cotransfecting miR-221 or -222 in the presence of 
the SCD5 3′UTR. As controls, mutated 3′UTR sequences and a non-targeting 
oligomer were also included. 
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Literature data established that microphthalmia-associated 
transcription factor (MITF), in axis with recombination signal 
binding protein J kappa (RBPJK), binds and represses miR221/-222 
promoter thus preventing effectively initiation of melanoma 
invasion (Golan T., 2015). In fact, MITF high levels  are recognized 
as suppressor of invasion and metastases formation, while low 
levels correlate with a high metastatic potential. (Cheli Y., 2012; 
Thurber AE., 2011). MITF is also recognized as a major regulator 
in “phenotypic switching”, thus and explaining at least in part the 
high plasticity of melanoma cells (Goding CR., 2011;  Vandamme 
N., 2014). A375M metastatic melanoma cell line express barely 
detectable level of endogenous SCD5 in parallel with low 
expression levels of MITF and high levels of miR221/-222 
(Felicetti F., 2008). This picture correlate with their aggressive 
phenotype and high metastatic potential. So, we selected this 
melanoma cell line to enforcedly express SCD5 and evaluate first of 
all, the effect of reconstituted SCD5 expression on MITF and 
miR221-222 axis. For this purpose we utilized a lentiviral vector 
system. SCD5 was correctly transcribed and translated in the 
transduced cells (Fig. 19 A-B) with approximately 200-fold 
increase of mRNA paralleled by a 30-fold increment of the SCD5 
protein compared with control empty vector-transduced cells. We 
also evaluated by GM/MS the levels of fatty acids (palmitic C16:0, 
stearic C18:0, palmitoleic C16:1 and oleic acid C18:1) in SCD5 and 
control vector-transduced A375M cell line demonstrating that the 
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stearic to oleic conversion was significantly enhanced by SCD5 
overexpression (see the ratio C18:1/C18:0) (Fig. 19 C), reaching a 
4-fold increase of oleic acid compared to control cells and 
comparable to the average level of primary melanomas (Fig. 19 D). 
Conversely, the ratio between palmitoleic and palmitic acid 
(C16:1/C16:0) remained almost unchanged (Fig. 19 C). These 
results demonstrate that the enzymatic action of SCD5 was 
preferentially addressed in OA synthesis.  
 
 
 
 
 
 
 
Fig 19: SCD5 enforced expression in A375M metastatic melanoma cells 
and GM/MS analyses 
 (A) qRT-PCR and B) Western blot analysis of SCD5- and Tween-
transduced controls. (C) SCD5 overexpression significantly increases the 
desaturation indexes, represented by the palmitoleic:palmitic (C16:1/16:0) 
and oleic/stearic (C18:1/18:0) acid ratios evaluated by GC/MS in metastatic 
melanoma cell line (p<0,01). (D) GC/MS-based quantification of 
endogenously produced oleic acid at different stages of melanoma 
progression; representative experiments are shown; levels of SCD5 and oleic 
acid are shown as fold changes compared to NHEM.  
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Western blot and immunofluorescence analyses evidenced that 
SCD5 transduced A375M cells were able to upmodulate MITF 
expression (Fig. 20 A-B). Then, we also evaluated whether 
miR221/-222 expression was also modulated. QRT-PCR confirmed 
a significant reduction of miR221/-222 transcription compared to 
control cells (reduction ranging from ≈ 60-40%) (Fig. 20 C) thus 
demonstrating that SCD5 takes part to MITF/ miR221/-222 axis 
regulation. We then considered that differentiation, proliferation and 
survival of melanocytes largely depend on MITF (Park HY., 2009; 
Sommer L., 2011). According to MITF-dependent re-establishment 
of differentiation program, we observed the activation of 
melanogenesis-linked protein tyrosinase (TYR) (Fig. 20 B), 
eventually underlined by increased melanin content (Fig. 20 D).  
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Fig 20: SCD5 favors melanoma differentiation in A375M metastatic 
melanoma cell line 
(A-B) Immunofluorescence and western blot analyses performed on SCD5-
overexpressing A375M melanoma cell line evidenced the capability of SCD5 
to upregulate MITF expression compared to empty-vector control, eventually 
associated with increased (B) tyrosinase. (C) QRT-PCR evidenced a significant 
reduction of miR-221/-222 transcription in SCD5 overexpressing cells 
compared to control. (D) cellular melanin content.  
 
 Results  
69 
 
6. SCD5 ENFORCED EXPRESSION: IN VITRO AND IN VIVO 
STUDIES 
To characterize more in depth the functional role of SCD5 in 
melanoma, a number of functional analyses were performed either 
in-vitro, as proliferation, invasion, migration and agar forming foci, 
or in-vivo in A375M cells, transduced or not with SCD5.  
The proliferative rate of melanoma cells, overexpressing or not 
SCD5, was performed by using a colorimetric assay XTT-based, 
demonstrating the lack of significant SCD5-dependent effects on 
cell growth. To assess whether SCD5 interferes with the 
dissemination abilities of melanoma cells, we utilized a Boyden 
chamber based assays, either uncoated or coated with matrigel 
inserts, to evaluate migration and invasion. We also verify the 
effects of SCD5 enforced expression on the ability to form foci in 
semisolid agar. Results showed slightly, but significantly decreased 
invasion, migration and foci numbers in SCD5-transduced A375M 
cells in comparison to empty vector controls (Fig. 21 A-B-C).  
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The above results support the hypothesis of SCD5 role in 
preventing melanoma metastatic spread, at least in part via stearic to 
oleic acid conversion. To confirm such results in vivo, SCD5- and 
empty vector-transduced A375M melanoma cells were injected into 
immunocompromised mice.  
Female of six-to-eight week old athymic Nu/Nu mice were utilized 
for human melanoma xenograft experiments. Animals were divided 
into two different groups and injected either subcutaneously (s.c.) 
(~10
6
 cells) in the flanks or intravenously (i.v.) with SCD5- or 
Fig 21: SCD5 overexpression in A375M metastatic melanoma: in-vitro 
studies 
Comparison  between A375M/Tween and A375M/SCD5 cells for A) cell 
growth proliferation, B) invasion  and migration capabilities and  C) foci 
number obtained in semisolid medium (down, representative images of foci).  
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empty vector-transduced A375M melanoma cells (see Table 3 for 
each experimental set up). 
 
 
Monitoring studies  revealed that, despite similar in-tumor take and 
growth at the primary site, SCD5-transduced A375M, but not 
Tween control cells, were hampered in metastasis formation at the 
lung site (p<0.01) (Table 4 and Fig. 22 A-B).  
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Tumor primary nodules were recovered and analyzed by 
immunohistochemical analyses to assess the number of mitotic cells 
and Ki67 staining. SCD5- and Tween-transduced cells, showed no 
Fig 22: Functional effects of SCD5 enforced expression: in-vivo studies 
Control Tween- and SCD5- transduced A375M metastatic melanoma cells 
were evaluated for: (A) tumor growth at the primary site at the indicated 
time points after subcutaneously (s.c.) injection into athymic nude mice; 
(B) total number of lung metastases  obtained through intravenous (i.v.) 
injection (p<0.01, top) and representative picture of lung metastases 
(bottom).   
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differences in cell proliferation according to in vitro results (Fig. 23 
A-B-C).  
 
 
 
 
 
 
However, the histological analysis of primary tumors indicated the 
presence of more numerous spindle-like cells in Tween- vs SCD5-
transduced tumors, the latter also characterized by a less fibrotic 
morphology with an intracellular accumulation of collagen, as for 
Masson’s trichromic and Gomori’s stainings (Fig. 24), suggesting 
that a reduced extracellular matrix (ECM) deposition could be 
associated with less metastases in SCD5-derived tumors.  
Fig 23: Analyses of tumor nodules excised from Nu/Nu athymic mice 
subcutaneously injected  
with A375M/Tween and A375M/SCD5 cell lines.  
(A) Ki 67 nuclear staining analysis obtained with the Image J software, 
(B) mean number±SD of mitosis and (C) Ki67 positive cells. Differences 
are not statistically significant. 
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In melanoma SPARC is required for tumor progression and its 
expression represents a marker of poor prognosis (Girotti MR., 
2011). Considering that the staining of primary tumor nodules 
evidenced a clear reduction of collagen extracellular deposition, a 
picture reminiscent of SPARC-deficient mice (Chavey C., 2006), 
we looked at possible connections between SCD5 and this 
matricellular protein. To this end, we performed IHC analyses of 
COLLAGEN IV and of its chaperone protein SPARC (Chiodoni C., 
2010). Data clearly showed that SCD5 restored expression was able 
to favor the intracellular accumulation of both SPARC and collagen 
IV, associated with their reduced extracellular release (Fig. 25 A). 
Fig 24: Histological evaluation of primary xenografted  tumors derived 
from A375M/Tween  in comparison with A375M/SCD5 
Representative images of Gomori’s and Masson’s trichromic staining 
showing a less fibrotic morphology associated with intracellular 
accumulation of collagens in SCD5-transduced tumors. 
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Western blot analysis performed on proteins extracted from the 
same tumor nodules confirmed the significant increase of SPARC 
in SCD5- respect to Tween-transduced A375M tumors (Fig. 25 B). 
 
 
 
 
 
 
To dissect these data, we reevaluated them in vitro by comparing 
the amounts of secreted SPARC in the conditioned media (CM) of 
Fig 25: SPARC expression in primary tumor nodules. 
(A) Representative IHC shows SPARC expression level and localization in 
nodules obtained after s.c. injection of Tween- and SCD5-A375M cells; 
magnification= 40X. (B) Immunoblot of total protein extracted from 
primary nodules excised from Nu/Nu mice injected s.c. with Tween- or 
SCD5-transduced A375M cells.  
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advanced and primary melanoma cells. We observed that metastatic 
melanoma cell lines released amounts of SPARC significantly 
higher than primary ones (Fig. 26 A). We next assessed the effects 
of SCD5-silencing in the WM983A primary melanoma, which 
express high endogenous level of SCD5. Notably, the 
downregulation of SCD5 was significantly associated with 
increased SPARC release (Fig. 26 B). Conversely, SCD5 enforced 
expression in A375M metastatic melanoma cells turned out in a 
considerable intracellular accumulation of SPARC at expenses of its 
secreted form (Fig. 26 C). Immunofluorescence analysis evidenced 
that SPARC was mostly retained into the trans-Golgi perinuclear 
area in parallel with COLLAGEN IV accumulation into the 
cytoplasm of SCD5-transduced melanoma cells (Fig. 26 D). 
According to the observed differences in SPARC localization but 
not in its quantity, qRT-PCR analyses showed no variation in 
SPARC steady-state mRNA levels in SCD5-transduced compared 
to control cells (Fig. 26 E).  
SPARC is also known to cooperate with CATHEPSIN B protein in 
favoring invasiveness (Girotti MR., 2011). CATHEPSIN B belongs 
to the family of lysosomal cysteine proteases and plays an important 
role in intracellular proteolysis. 
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Fig 26: Regulation of SPARC expression 
Western blots of endogenous SPARC levels evaluated on: (A) cell lysates 
(CL) and conditioned media (CM) from representative primary/low-invasive 
and metastatic melanomas; SPARC immunoblots of (B) SCD5-silenced 
WM983A primary melanoma and (C) SCD5-over-expressing A375M 
metastatic cell line. (D)  Immunolocalization analysis showing the 
intracellular accumulation of both SPARC (red) and Collagen IV (green) in 
A375M/SCD5 compared to A375M/Tween. (E) QRT-PCR of SPARC 
expression in A375M/SCD5 compared withTween empty vector control. 
Scale bar=10 µm 
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Upregulation of this secreted protein can be found in premalignant 
lesions as well as in other pathological condition, as cancer itself 
(Tong B., 2014; Lai WF., 2004; Ha SD., 2010; Yang WE. 2016). It 
is also involved in autophagy and cannibalism, which is 
advantageous in tumor malignancy and is possibly involved in 
specific immune resistance (Fais S., 2007). As indicated by SPARC 
retention, the reduced propensity to secrete proteolytic enzymes and 
prometastatic molecules by SCD5-overexpressing melanoma cells 
was also confirmed by the parallel intracellular retention of 
CATHEPSIN B (Fig. 27 A).  
As lysosomes represent the main storage of cathepsins, including 
CATHEPSIN B, which is are known to localize at the cell periphery 
in advanced melanoma and at the perinuclear region in less 
malignant tumors we analyzed the cellular distribution and 
localization of Lysosome-Associated Membrane Proteins 2 
(LAMPs). According to the reduced malignancy of SCD5-
transduced cells, confocal analysis evidenced LAMP2 positive 
vesicles redistributed in the nuclear proximal area, while in control 
cells these vesicles are scattered into the cytoplasm on the way to 
the cell membranes. A parallel strong accumulation of 
CATHEPSIN B, reminiscent of SPARC distribution and mostly 
colocalizing with LAMP2, was detected in the same area (Fig. 27 
B). It is worth noting that most of the accumulated CATHEPSIN B 
was in its mature form, as demonstrated by the Magic Red assay 
that specifically detects its activated fraction, indicating that the 
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reduced secretion of this cysteine protease was not due to a failure 
in protein maturation (Fig. 27 C).  
 
 
 
 
 
 
 
 
7. EFFECTS OF OLEIC ACID EXOGENOUS 
SUPPLEMENTATION 
Knowing from literature data the existence of  a direct link between 
γ-linoleic acid and SPARC secretion in breast and colon cancer cell 
Fig 27: SCD5-dependent regulation of CATHEPSIN B activity 
(A) CATHEPSIN B immunoblot in SCD5-overexpressing A375M metastatic 
cell line. (B)  A significant intracellular accumulation of CATHEPSIN B (red) 
and LAMP2 (green) with colocalization is appreciable. It is notable the change 
of vesicles distribution in SCD5-compared to empty vector transduced cells, 
primarily perinuclear in the former and more peripheral in the latter, according 
to malignant progression. (C) Intracellular CATHEPSIN B activity detected by 
using a Magic Red-(RR)2 CATHEPSIN B fluorogenic substrate demonstrating 
that a substantial fraction of CATHEPSIN B accumulated in SCD5-transduced 
A375M is in its active form. Scale bar=10 µm 
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lines (Watkins G., 2005) and considering the preferential role of 
SCD5 in the conversion of stearic to oleic acid (OA),  we evaluated 
whether the exogenous supplementation of OA could reproduce the 
same effects of SCD5 gene transduction.  
The A375M/Tween melanoma cell line cultured in low serum 
condition (1%) in order to favor the intracellular uptake of 
exogenous lipids, was subjected to a time course treatment (up to 
day 6) with different doses of oleic acid (OA) (10 to 100 µM) or left 
untreated (Fig. 28 A). After 3 days of treatment, with either 50 or 
100 μM of OA, the intracellular accumulation, with a parallel 
reduction of the secreted form of SPARC, which was comparable to 
that induced by SCD5 gene transduction (Fig. 28 B). This result 
indicated that most of the SCD5-dependent effects on melanoma 
cells passes through the production of OA.  
The specificity of OA action was confirmed by testing palmitoleic 
acid (PA) that did not show any effect on SPARC and CATHEPSIN 
B secretion in A375M cells (Fig. 28 C).  
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Fig 28: Effects of oleic (OA) and palmitoleic (PA) acids on SPARC and 
CATHEPSIN B secretion  
(A) Dose–response of OA-treated A375M/Tween cells, evaluated by 
immunoblots at different time points; SPARC and cathepsin B levels were 
compared with those of SCD5-transduced A375M cells.  Immunoblot of 
cell lysate (CL) and conditioned medium (CM) of A375M/Tween cells 
treated for 3 days with the indicated concentrations of (B) oleic acid (OA) 
or (C) palmitoleic acid (PA). 
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8. SCD5 INDUCES INTRACELLULAR pH ACIDIFICATION 
The extracellular pH (pHe) of tumor tissues is often acidic 
(Warburg O., 1927) and acidic metabolites, e.g. lactic acid, 
produced by anaerobic glycolysis in hypoxia condition, the so 
called Warburg effect, seem to be the main underlying cause. Acid 
pHe not only favors the activation of some lysosomal enzymes, but 
also induces the expression of some pro-metastatic genes. 
Lysosomal enzymes have an acidic optimal pH and some tumor 
cells have the ability to secrete them, such as CATHEPSIN B and 
cathepsin L (Rofstad EK., 2006). Cathepsin K plays an important 
role in osteoclast-mediated bone reabsorption (Karsdal MA., 2005; 
Saftig P., 1998) and its inhibition prevents breast cancer-induced 
osteolysis and skeletal tumor burden (Le Gall C., 2007). Thus, 
osteoclast mediated acidic pHe leads to mineral dissolution and 
activation of cathepsins to digest bone matrix, such as type I 
collagen. Podgorski and coauthors (Podgorski I., 2009) reported 
that SPARC, a major non-collagenous protein in bone, is digested 
by cathepsin K and its fragments are associated with bone-
metastasis formation.  
As showed by results obtained for SPARC and CATHEPSIN B, 
which are intracellular accumulated in SCD5-overexpressing cells 
compared with empty vector controls, we evaluated the competence 
of SCD5 in modifying the acidification gradient between tumor 
cells and microenvironment, as reported for some fatty acids which 
can reduce the intracellular pH, possibly delaying the vesicular 
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maturation process (Wu ML., 2000). Hence, we evaluated the 
intracellular acidity of Tween- and SCD5-transduced A375M 
melanoma cells using a pH-dependent reversible fluorogenic probe 
and analyzing the emission profiles by a microplate-based 
fluorimetry. According to our hypothesis, the intracellular pH was 
lower in A375M/SCD5 cells than in A375M/Tween controls (Fig. 
29 A), thus suggesting  the existence of a reversed pH gradient 
associated with reduced malignancy (Whal ML., 2002). The 
addition of four pH calibration buffers, allowed establishing the 
intracellular pH, indicated as pH≥7.4 for control cells and ≤7.0 for 
SCD5-transduced cells. According to the described role of oleic 
acid in regulating proton extrusion (Grasso EJ., 2011), A375M 
control cells treated with growing doses of oleic acid displayed a 
gradual reduction of pH, ranging from 7.4 at 20 µM to 6.5 at 100 
µM (Fig. 29 B), confirming the parallel roles of SCD5 and OA in 
intracellular acidification.  
Accumulating evidence shows that an acidic microenvironment is 
associated with reduced proton extrusion and is regulated by 
different integrated membrane proteins being. While Na+-HCO3-
co-transporter and Cl-/HCO3-exchanger contribute to decrease in 
the intracellular pH, the Na+/H+ exchanger (NHE) (Chesler M., 
1985), the H+-lactate co-transporter, monocarboxylate transporters 
(MCTs), and the H+-ATPase (H+ pump) are responsible for the 
secretion of H+ (Nishisho T., 2011).  
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Fig 29: Determination of intracellular pH by using the pHRhodo 
fluorescent dye 
Intracellular pH evaluation in (A) A375M/Tween vs A375M/SCD5 and 
(B) A375M/Tween cells treated for 48 h with 100 µM oleic acid. The red 
triangles indicate the intracellular pHs determined according to the 
reported plots. 
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As multi-subunit vacuolar ATPases (V-ATPases) are one of the key 
regulator family of extracellular pH, in that generate the acidic 
metastatic microenvironment pumping protons outside the cells 
(Pérez-Sayáns M., 2009), we investigated their possible 
involvement in the SCD5-dependent intracellular acidification. Our 
gene profiles studies (Fig. 30 A) indicated the downregulation of 
five V-ATPase subunits. Among them we focused on the most 
decreased ones, ATP6V1C2 and ATP6V1G2, reduced 4 and 3.5-
fold respectively.  
Western blot and IF analyses confirmed ATP6V1C2 
downregulation in the A375M/SCD5 cellular model (Fig. 30 B-C). 
Conversely, the ATP6V1G2 one does not appear significantly 
modulated.  
All together our results indicate a significant role of OA in lowering 
the intracellular pH at least in part through the reduced activity of 
the V-ATPase C2 subunit.  
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8.1. ACIDIC CULTURE CONDITIONS RESTORE SPARC AND 
CATHEPSIN B SECRETION 
As a correct acidification appears crucial for proper activation and 
trafficking of proteins and proteases involved in tumor initiation 
Fig 30: SCD5-dependent regulation of the V-ATPase subunit 
ATP6V1C2 
(A) Gene expression profile indicated the SCD5-dependent decrease of 5 V-
ATPase subunits (in red V1C2 we selected for futher analysis). (B) Western 
blot analysis confirmed the down-regulation of the ATP6V1C2 subunit in 
A375M cells, without any  apparent change in cellular localization, as 
confirmed by (C) immunolocalization studies. 
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and progression, control and SCD5-transduced melanoma cells 
were cultured at low pH and compared with cells grown at buffered 
conditions (pH 6.0 vs 7.4). Interestingly, in SCD5 overexpressing 
cells the extracellular acidic conditions were able to unblock 
SPARC and CATHEPSIN B intracellular retention, allowing their 
secretion. A time response analysis, performed by Western blot on 
proteins, either recovered from cell lysates or from the 
corresponding conditioned media, showed that after 12h at pH 6.0 
the amounts of SPARC released by A375M/SCD5 cells were 
comparable to those of control cells. An identical expression pattern 
was observed for the intracellular levels of CATHEPSIN B (Fig. 31 
A-B).  
Strong evidence of extracellular acidic pH capability to restore the 
malignant secretory pathway came from confocal microscope 
analysis of SPARC and CATHEPSIN B in Tween- and SCD5- 
transduced A375M cells. 
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Acidification of the external pH (pHe< pHi) was able to drive both 
SPARC and CATHEPSIN B toward the cellular periphery (Fig. 32 
A-B). It is important to note the different secretory patterns 
followed by these two proteins, being CATHEPSIN B localized in 
Fig 31: Acidic culture conditions restore SPARC and cathepsin B 
secretion in A375M/SCD5 cells 
Western blots of A375M/Tween and A375M/SCD5 cell lysates (CL) and 
conditioned media (CM) obtained from cells cultured at (A) pH 7.4 or (B) pH 
6.0. 
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discrete punctuate vesicles and SPARC more diffused into the 
cytoplasm. Unlike SPARC, we were unable to detect the secreted 
fraction of CATHEPSIN B in the CM, possibly because of its quick 
degradation (Almeida PC., 2001). Looking for the option of a 
protein cargo protected from circulating nucleases and proteases, we 
isolated the microvesicles (MVs) released in the extracellular 
medium by Tween- and SCD5-transduced A375M, grown at neutral 
or acidic conditions. Notably Tween-derived microvesicles (MVs) 
contained comparable amounts of CATHEPSIN B, either at pH 7.4 
or pH 6.0, whereas a significant increment was induced by the 
extracellular acidic culture conditions in A375M/SCD5-derived 
MVs, once more indicating that the SCD5-dependent impairment 
could be overcome by low pH. The same expression pattern was 
observed for SPARC. As representative MV markers, CAVEOLIN-
1 and RAB5b protein levels were evaluated too. As expected, their 
pattern was essentially unchanged (Fig. 32 C).  
Finally and according to the functional roles played by SPARC and 
CATHEPSIN B in the invasion program of melanoma cells, their 
restored secretion stimulated by the low pH was associated with 
increased invasion and migration of A375M/SCD5 cells (Fig. 33 A-
B).  
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Fig 32: Immunolocalization analyses of SPARC and CATHEPSIN B 
cellular localization in buffered (pH 7.4) and acidic (pH 6.0) cell 
cultured condition 
(A, B) Confocal microscopy of SPARC and CATHEPSIN B in Tween- 
and SCD5-transduced A375M cells at the indicated pHs. (C) 
A375M/Tween- and A375M/SCD5-derived microvesicles from CM of 
cells cultured at pH 7.4 or 6.0 evidencing a significant increment of 
secreted CATHEPSIN B when  SCD5 overexpressing cells were cultured 
in acidic conditions.     
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9. SCD5 FUNCTIONAL ROLE IN THE MURINE MAMMARY 
CARCINOMA CELL LINE 4T1 
In order to further validate SCD5 Δ9 desaturase role, we also 
utilized the murine mammary carcinoma cell line 4T1, a very useful 
in vivo model of spontaneous metastases. Four desaturases, SCD1 
to SCD4, exist in mice (Wang J., 2005), all showing a certain 
Fig 33: Boyden chamber assay evaluation of migration and invasion 
(A) Crystal violet staining of A375M/SCD5 cells able to migrate and invade 
at neutral (pH 7.4) and acidic (pH 6.0) conditions. (B) Densitometric 
evaluation shows a significantly increased capability at  acidic (pH 6.0) 
conditions (p<0.05). 
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degree of homology with human SCD5, but no one exactly being its 
homologous. As for A375M metastatic melanoma model, we 
overexpressed SCD5 by transducing the 4T1 cells with the 
lentivirally vector Tween (Fig. 34 A-B).  
We then evaluated the fatty acids contents (Palmitic and stearic 
acids (C16:0/C18:0, palmitoleic and oleic acids (C16:1/C18:1) by 
using GM/MS analyses evidencing the preferentially induction of 
oleic acid toward the palmitoleic one also in this cell model (Fig. 34 
C).  
Accordingly and in agreement with melanomas, SCD5-transduced 
and oleic acid-treated 4T1 cells displayed SPARC intracellular 
accumulation (Fig. 35 A). In vitro analysis confirmed the reduced 
malignancy associated with SCD5 as indicated by reduced cell 
migration in wound healing experiments (Fig. 35 B).  
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Fig 34: SCD5 enforced expression in 4T1 mammary carcinoma cell 
line: desaturation index analysis 
A) QRT-PCR, B) Western blot  comparison between SCD5-transduced and 
Tween controls 4T1 cells. (C) Increased desaturation indexes, represented 
by the palmitoleic:palmitic (16:1/16:0) and oleic/stearic (18:1/18:0) acid 
ratios, evaluated by GC–MS in  4T1 cell lines, transduced with SCD5 
(p<0.01). 
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Fig 35: Functional effects of SCD5 enforced expression in murine 4T1 
mammary carcinoma cell line 
(A) Western Blot  analyses of SPARC performed on cell lysates (CL) of 
SCD5-overexpressing compared withTween control. (B) Wound healing 
assay to compare migratory capability.    
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Basing on the capability of 4T1 cells to spontaneously produce 
distant micrometastases in syngeneic BALB/c mice, we carried out 
some additional in vivo experiments.  
The experimental animal groups, subcutaneously injected with 
SCD5- or Tween-transduced vector control 4T1 cells (~ 7x10
3
) 
(Table 5) confirmed the SCD5-dependent significant hampering of 
lung micrometastases formation (p<0.005), whereas only a slight 
reduction of primary tumor volumes was observed (Table 6, Fig. 36 
A-B).  
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Masson colorimetric assay and IHC analyses performed on tumor 
nodules confirmed the capability of SCD5-overexpressing cells in 
decreasing extracellular collagen deposition, particularly collagen 
Fig 36 : Functional effects of SCD5 enforced expression in 4T1 mouse 
mammary carcinoma model: in-vivo studies 
(A) In-vivo growth of primary tumors after s.c. injection of 4T1 cells in 
BALB/c syngeneic mice. (B) Lung micrometastases evaluation by 
clonogenic assay (p<0,001).  
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IV (Fig. 37). It is worth noting that also in 4T1 murine mammary 
carcinoma model in presence of SCD5 was observed a 
downmodulation of miR221/-222 (Fig. 38), suggesting the possible 
regulatory function translational function of SCD5 in different 
tumor models.  
 
 
 
 
 
 
 
 
Fig 37: Hystological and Immunohystochemical analyses on primary 
tumor nodules 
Masson’s trichrome staining and COLLAGEN IV IHC on primary nodules 
obtained after s.c. injection of Tween- and SCD5- transduced 4T1 cells; 
IHC magnification=×20 
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Fig 38: Mir221/-222 expression levels in 4T1 transduced cell lines 
QRT-PCR evidenced a significant reduction of miR221/-222 
transcription in SCD5 overexpressing cells  
compared to control.  
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DISCUSSION 
The deregulated metabolic activities displayed by cancer cells 
require a constant supply of energy and the availability of 
appropriate structural membrane components. In fact cellular lipids, 
including fatty acids, play a fundamental role in sustaining the high 
rate of proliferation and signal transduction of cancer cells. Also a 
correct balance between saturated and unsaturated lipids is required 
for the maintenance of cell homeostasis in normal cells (Ackerman 
D., 2014). Recent results have clearly recognized the central role 
played by bioactive lipids and fatty acids as mediators of the 
crosstalk between cancer cells and stroma (Beloribi-Djefaflia S., 
2016).  
Mediterranean diet is characterized by high olive oil consumption 
and a wide range of experimental observation have evidenced its 
protective role in breast, colorectal, colon and glioma tumor model 
(Trichopoulou A., 2000Chajes V., 2008; Bautista D., 1997; 
Stoneham M., 2000; Bartoli R., 2000) possibly through its main 
component oleic acid (OA). Accordingly, OA induces TNFα 
production in RAW264.7 macrophages (Liu X., 2010) and impairs 
tumor neovascularization inhibiting VEGF receptor/MAPK 
pathway (Lamy S., 2014). On the contrary, palmitoleic acid is 
synthesized upon stimulation with growth factors, mainly bFGF and 
PDGF, and is able to amplify mitogenic signals (Koeberle A., 
2012).  
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In humans the main enzymatic activity of SCD5, and of its homolog 
SCD1, provides the desaturation of two main substrates, palmitic 
and stearic acid, producing palmitoleic and oleic acid.  
Contrary to the virtually unknown role of SCD5, some of the 
biological effects of SCD1 desaturase activity in cancer are already 
reported (Nashed M., 2012; Huang J., 2016, Angelucci C., 2015). 
Over-expression of SCD1 is associated with cell metabolism, 
proliferation and progression of several solid tumors (Chen L., 
2016). 
We focused on SCD5 potential role in melanoma, starting from its 
down-regulated expression in human melanoma cell lines and 
bioptic specimens during progression (Fig. 12 A-B). Searching for 
the mechanisms underlying such significant expression decrease, 
we unveiled the effectiveness of different post-transcriptional 
regulatory system among primary and metastatic samples. Indeed as 
confirm of its possible antimetastatic role, we demonstrated the 
SCD5 epigenetic silencing in advanced melanoma samples 
compared to primary ones (Fig. 14 A-B). In addition SCD5 protein 
appears more stable in primary melanomas compared to metastatic 
ones (Fig. 16 A-B). For long time, both these isoenzymes were 
considered to play similar desaturation function on saturated fatty 
acids. It is now important to evidence some specificity discerning 
SCD1 and SCD5. For example, their distribution appears different 
in normal tissues, being SCD1expressed in the majority of them, 
while SCD5 is present only in human pancreatic and brain cells 
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(Igal RA., 2010). Moreover, at least in melanoma cells, our results 
evidenced an unexpected specific desaturating function of SCD5 
compared to SCD1. In fact, GM/MS analysis on SCD5 
overexpressing cells demonstrated an increase of desaturation index 
compared to Tween  control, preferentially  evidenced in oleic acid 
increase (3:1 ratio), indicating a specific action on stearic compared 
to palmitic acid desaturation (Fig. 19 C). In addition, our 
experimental evidences show that SCD1 protein was rapidly 
degraded after cycloheximide treatment both in primary and 
metastatic melanoma cell lines, according to literature data 
confirming its proteasome dependent degradation (Kato H., 2006). 
Despite this high rate of degradation, SCD1 appears highly 
expressed at all tumor stages indicating that SCD1 levels appear 
principally determined by its rate of transcription (Igal RA., 2010). 
Notably, the different protein half-life between SCD5 and SCD1 
might be important to increase the oleic acid production at expense 
of palmitoleic, thus sustaining SCD5 expression in primary 
melanomas (Fig. 16 A-B and Fig. 19 C) and reducing cell 
aggressiveness.  According to GC/MS in melanoma cells SCD1 
does not show the same preferential enzymatic activity toward oleic 
acid production (our unpublished data), whereas the decline of 
SCD5 matched with oleic acid reduction during melanoma 
progression. In general, SCD1 appears to play a pro-tumorigenic 
role, whereas, our data evidence as SCD5 exert a tumor suppressor 
function.  
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In view of our previous studies on microRNA functional roles in 
melanoma, we made a particular focus on the SCD5/miR regulatory 
system. We observed an inverse correlation between the expression 
levels of SCD5 and miR221/-222 a well known couple of 
tumorigenic microRNAs (Fig. 17 A-B) (Ciafrè SA., 2005; Visone 
R., 2007; Garofalo M., 2009; Miller Te., 2008; Medina R., 2008; 
Felicetti F., 2008). Luciferase assays and functional experiments, 
based on miR221/-222 overexpression or silencing, evidenced the 
existence of miR-dependent regulatory mechanism on SCD5 (Fig. 
18 A-B-C-D), again confirming our hypothesis of the necessity to 
limit the expression of this desaturase during melanoma 
progression. 
The idea that SCD5 restored expression or oleic acid 
supplementation might antagonize the aggressiveness of advanced 
melanoma was sustained by the capability of SCD5 overexpression 
to diminish in-vitro invasiveness and chemotaxis of metastatic 
melanomas (Fig. 21 B-C). More importantly, this reduction was 
evident in-vivo by intravenous-induced metastasis of human 
A375M/SCD5 melanoma cell line (Fig. 22-B). The same in vivo 
results were also found in murine mammary carcinoma 4T1 cell line 
overexpressing the human SCD5 gene (Fig. 36 B-C). This cell line 
was employed for the capability to spontaneously produce distant 
metastases in syngeneic BALB/c mice tumor model. The formation 
of spontaneous metastases was significantly impaired whereas only 
a slight reduction of primary tumor volumes was observed.  
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Both the in vivo experiments evidenced the importance of ECM 
deposition and modification necessary for tumor dissemination and 
metastatic niche formation. Cancers are not just masses of 
malignant cells, but complex “organs” where many other cells are 
recruited to be corrupted by transformed cells (Balkwill FR., 2012). 
Therefore the complex crosstalk between tumor cells and the 
microenvironment is one of the factors that limit treatment efficacy 
(Ruiter D., 2012). We looked for SCD5-dependent regulation of 
ECM, knowing that the matricellular protein SPARC is necessary 
for melanoma progression (Ledda MF., 1997) and that its transcript 
is highly expressed at radial to vertical growth phase transition 
(Sturm RA., 2002). Either SCD5 transduction or oleic acid 
supplementation elicited a strong intracellular retention of collagen 
IV and SPARC (Fig. 26 C-D in advanced melanoma, resembling 
that observed in in vivo studies (Fig. 25 A-B). A similar effect on 
SPARC was previously described for γ-linoleic acid in breast and 
colon cancer cell lines (Watkins G., 2005). Contrary to decreased 
cell survival and proliferation associated with SPARC silencing 
(FenouilleN., 2011, Fenouille N., 2011) our data, showing reduction 
of extracellular SPARC in favor of its cytoplasmic form, suggest 
the possibility of additional unknown roles specifically played by 
intracellular SPARC. Abnormal accumulation of SPARC was also 
observed in the endoplasmic reticulum of patients with pseudo-
achondroplasia (Hecht JT., 2006), reminiscent of the abnormal 
retention of collagens observed in other connective diseases (Byers 
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PH., 2012). Along with SPARC, cathepsin B, another secreted 
protein involved in migration and invasion of solid tumours 
(Podgorski I., 2003; Mohanam S., 2001) including melanoma 
(Szpaderska AM., 2004), was retained intracellularly in the 
presence of SCD5. The reduced propensity to secrete proteolytic 
enzymes and prometastatic molecules by SCD5-over-expressing 
melanomas was supported by LAMP2, a representative lysosomal 
protein (Glunde K., 2003), which is known to localize at the cell 
periphery in advanced melanoma and at the perinuclear region in 
less malignant tumors, including SCD5-transduced cells (Fig. 27 B-
C). Insight into the underlying mechanisms came from testing 
whether SCD5-dependent intracellular oleic acid production might 
reduce the internal cellular pH, and therefore vesicular trafficking, 
across the plasma membrane. In-vitro growth at acidic extracellular 
pH increases the rate of experimental pulmonary metastases in 
athymic nude mice in different melanoma cell lines (Rofstad EK., 
2006). This increase likely results from anaerobic utilization of 
glucose, increased H+ proton efflux and hyperactivation of proton 
extruder proteins, as V-ATPase and Na+/H+ exchanger (NHE), 
according to a characteristic ’reverse gradient’ that favours cells 
able to grow in hypoxic conditions (Estrella V., 2013). Our 
experimental results indicated that a reduced SCD5- or oleic acid-
dependent intracellular pH is associated with a more physiological 
condition (pHe>pHi) (Fig. 29 A-B). Accordingly, a strong 
reduction of the extracellular acidity (pH 6.0), besides restoring the 
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reversed pH gradient (pHe<pHi) characteristic of tumor cells at the 
microenvironment boundaries, was able to re-establish SPARC and 
cathepsin B secretion, in turn promoting the tissue remodeling 
required for tumor cell spreading (Fais S., 2010). As cancer cells 
depend on the secretion of proteases to invade tissue and form 
metastases, inhibition of V-ATPase might hamper the secretion 
profile of cancer cells, therefore interfering with their metastatic 
properties (Pérez-Sayáns M., 2009). Thereby, SCD5-transduced 
cells show reduced levels of the V-ATPase subunit C2 (Fig. 30 B-
C), possibly explaining the less malignant phenotype associated 
with a decreased efficiency of this proton pump. Notably, subunit C 
mediates the binding of V-ATPase to the actin cytoskeleton, linking 
V-ATPase with actin fibers and in turn with cytoskeleton 
rearrangement and tumor dissemination (Cai M., 2014).  
In conclusion, these data demonstrate the antineoplastic role of 
SCD5 in melanoma and, more specifically, the increased 
malignancy associated with its barely detectable levels in melanoma 
metastatic phase. As oleic acid seems the main product of SCD5 
enzymatic activity and one of the main components of the 
Mediterranean diet, our data can offer an explanation to the 
beneficial effects associated with the regular consumption of olive 
oil and recommendation for cancer prevention. Treatment strategies 
including oleic acid or its derivatives in combination with other 
drugs and/or immunotherapy should also be considered.  
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MATERIALS AND METHODS 
10 CELLS  
10.1. CELL LINES CULTURE 
Most of the human melanoma cell lines used in the current study 
was stabilized from surgical specimens obtained from primary or 
metastatic tumors at the Istituto Nazionale Tumori in Milan (Italy). 
The A375 cell line was from the American Type Tissue Collection 
(Rockville, MD, USA) and its metastatic variant A375M was kindly 
provided by Dr R Giavazzi (Istituto Mario Negri, Bergamo, Italy). 
Normal human epidermal melanocytes from foreskin were obtained 
from Promocell (Heidelberg, Germany). 4T1 is a 6-thioguanine-
resistant cell line derived from a spontaneous mammary carcinoma 
(ATCC-LGC Promochen, Teddington, UK). Table 7 lists the 
analyzed melanoma cell lines. 
Tumor cells were cultured in Dulbecco’s modified Eagle’s medium 
(DMEM; Life Technologies, Paisley, UK) supplemented with 10% 
fetal calf serum (FCS) (BioWhittaker,Walkersville, MD, USA) and 
maintained in a humidified incubator (5% CO2, 37
°
C). 
All the cell lines were authenticated according to standard short 
tandem repeat (STR)-based genotyping (Banca Biologica e Cell 
Factory, IRCCS Azienda Ospedaliera Universitaria San Martino-
IST Istituto Nazionale per la Ricerca sul Cancro, Genova, Italy). 
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10.2. CLONING AND TRANSDUCTION 
Human SCD5 (NCBI Reference Sequence: NM_001037582.2) 
cDNA, encompassing its complete coding sequence was amplified 
from normal human genomic DNA using a Taq DNA polymerase 
high fidelity (AccuTaq) (Sigma-Aldrich, Saint Louis, MO, USA). 
(Table 8) by Polymerase Chain Reaction (PCR) (GeneAmp PCR 
System 9700, Applied Biosystem), sequenced (BMR Genomics 
Padova, Italy) and cloned into the lentiviral Tween-GFP vector . 
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10.3. LENTIVIRUS PRODUCTION AND INFECTION 
Lentiviral supernatants were produced by transient cotransfection of 
(a) DNA (Tween empty-vector or SCD5), (b) pCMV, (c) pMDG, 
with Lipofectamin 2000 (Life Technologies, Carlsbad, CA, USA) 
according to manufacturer’s instructions in the packaging human 
embryonic kidney cell line 293FT. Viral supernatants were 
collected 48h after transfection, filtered through 0.45μm pore 
nitrocellulose filters and used freshly on A375M melanoma or 4T1 
mammary carcinoma cell lines. 4μg/ml of polybrene was added to 
the viral supernatants to improve the infection efficiency. After the 
infection cycles, tumor cell lines were washed twice and fresh 
medium was replaced. Infection efficiency was evaluated after 48h 
by flow cytometry FACS Canto (Becton Dickinson, New Jersey, 
USA) 
Overexpression of miR-221 and -222 was obtained in primary 
melanoma cells by using a lentiviral vector system, as reported by 
Felicetti and colleagues (Felicetti F., 2008). 
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10.4. GENE SILENCING AND CELL TREATMENTS 
SCD5 was specifically silenced by using a validated small 
interfering RNA (IDT, Leuven, Belgium). Briefly, 48 h after 
plating, cells were transfected using Lipofectamine 2000 (Life 
Technologies) either with DsiSCD5 
(HSC.RNAI.N001037582.12.1_1) or with a DsiRNA scrambled 
control (Dsi-scr #64218602) used both at 200 nM. After 48h of 
transfection the level of SCD5 protein was analyzed by western blot 
analyses. Where indicated cells are treated with 5-aza-dC or TSA, 
actinomycin D, cychloeximide, MG132, palmitoleic or oleic acid, , 
(Sigma-Aldrich). 
 
10.5. PREPARATION OF CONDITIONED MEDIA IN 
BUFFERED AND ACIDIC CONDITIONS 
Human melanoma cell lines were seeded in 24-well culture dishes 
(10
5
cells/well) in DMEM 10% FCS v/v and maintained in a 
humidified incubator. After 24 h, the cells were washed once with 
Phosphate-buffered saline (PBS, Life Technologies, Paisley, UK) 
and DMEM 0.1% FCS added to each dish. The experiments were 
performed under either buffered (pH 7.4) or acidic (pH 6.0) 
conditions. For the latter, the pH of DMEM 0.1% FBS v/v was 
decreased by adding HCl. Cells and their respective CM were 
collected at 4–12 h, spun and either used immediately or stored at 
−80°C. 
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10.6. MICROVESICLES (MVs) ISOLATION 
Melanoma cells were cultured with DMEM medium supplemented 
with 10% FBS, previously deprived of bovine microvesicles (MVs) 
by ultracentrifugation (60min at 100 000 × g). MVs were then 
isolated from supernatants of exponentially growing cells by 
sequential centrifugations or by utilizing the ExoQuick-TC kit 
(System Biosciences). Samples were analysed by western blotting 
for SPARC and cathepsin B expressions, with RAB5b and CAV-1 
as positive controls. 
 
11. IN-VITRO ASSAYS 
11.1. AGAR FOCI 
Base layers of complete DME medium containing 0.5% agar were 
set in 60 mm plastic dishes. The bottom agar was overlaid with 1.5 
ml of 0.33% agar containing suspensions of 5x10
3
cells. Cultures 
were incubated for 3-4 weeks at 37°C and the colonies counted 
using an inverted microscope. Two experiments were performed for 
each cell line and results were calculated as the average ± SE of 
three dishes for each condition. 
 
11.2. PROLIFERATION 
The determination of cellular proliferation and viability was done 
by using cell proliferation kit II (XTT) (Roche, Mannheim, 
Germany) according to manufacturing procedures. Briefly the assay 
is based on the cleavage of the yellow tetrazolium salt XTT to form 
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an orange formazan dye by metabolic active cell, which is soluble 
in aqueous solution and is directly quantified using a scanning 
multiwall spectrophotometer. A proper number of cells were seeded 
in 96 well culture plate in DMEM 10% FCS v/v in a final volume of 
100ul and maintained in a humidified incubator  cells. Then cells 
are incubated with XTT labeling mixture and incubated for 2h at 
37°C. After this incubation period, orange formazan solution is 
formed, which is spectrophotometrically quantified (Victor X3, 
Wallac–Perkin-Elmer 2030 software v. 4.00) at 490nm. 
 
11.3. MIGRATION AND INVASION 
migration and invasion were assayed, as previously described 
(Felicetti et al., 2008), using cell culture inserts (Corning Costar 
Corporation) with 8μm pores uncoated or coated, respectively, with 
100g/cm2 of Matrigel growth factor reduced (Becton Dickinson) in 
order to mimic in-vivo barrier. Cells (5 10
5
) were placed in the 
upper compartment in 100 μl of DMEM serum-free, while 600 μl of 
DMEM supplemented with 10% FBS were placed into the lower 
compartment of the chamber. Assays were incubated at 37° C in 5% 
CO2. After 48h cells attached to the upper side of the membrane 
were removed with a cotton swab; each membrane was fixed 
(Glutaraldehyde 2.5%) and stained with crystal violet solution 0.1% 
for 30min at room temperature. After incubation, membranes were 
washed with distilled water and crystal violet staining was dissolved 
with acetic acid 10%. Migration and invasiveness were evaluated, 
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as relative number of cells on the undersurface of the membrane, by 
a colorimetric assay at 595 nm in a microplate reader (Victor X3, 
Wallac–Perkin-Elmer 2030 software v. 4.00). The data were 
expressed as the mean absorbance ± SE for triplicate wells. 
 
12. IN-VITRO ANALYSES 
12.1. QUANTITATIVE REAL TIME-PCR (qRT-PCR) 
QRT–PCR was performed according to the TaqMan technology 
(Applied Biosystems, Foster City, CA, USA), using the ΔΔCT 
method. Assay numbers were: SCD5v1 #Hs01125695_m1, SPARC 
#Hs00234160_m1, 18SrRNA #4319413E and GAPDH #4326317E. 
 
12.2. QUANTIFICATION OF FATTY ACIDS WITH GC–MS 
Melanoma cell lines grown for 72 h in DMEM 2.5% serum were 
trypsinized, washed three times in phosphate-buffered saline (PBS) 
and the cell pellets analysed by GC–MS. For either control vector- 
or SCD5-transduced cells, at least four different samples were 
evaluated. Quantification of fatty acids was conducted as previously 
described (Cai Q., 2013). Briefly, lipids were extracted with 
Folch/BHT reagent and the lower phase was collected and dried 
under N2. Methyl palmitate, palmitoleate, stearate and oleate (50 μl; 
4mg/ml isottane) were added to the extracts as an internal standard. 
Total tissue lipids were methyl-esterified with BF3/methanol (10%). 
The fatty acid methyl ester was analyzed by gas chromatography, 
using a Clarus 500 GC system (Perkin-Elmer) equipped with a 
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BPX70 capillary column and a flame ionization detector (FID) used 
to quantify fatty acids. 
 
12.3. WESTERN BLOT AND IMMUNOFLUORESCENCE 
Total cell lysates were prepared by using nonidep-p40 (NP-40). In 
brief cell pellets were resuspended in 30-50ul of NP-40 cell lysate 
buffer (1% NP40, 200nM NaCl, 50mM Tris pH7.4) plus protease 
inhibitor (IP) (0.5mM DTT and 0.2mM PMSF), maintained on ice 
for 30 min, vortexed and then centrifuged at 3000rpm for 10 min at 
4 °C. Proteins concentration was measured by Biorad protein-assay 
(Hercules, CA, USA). Western blot was performed according to 
standard procedures. Total cell lysates were separated by the precast 
NuPAGE polyacrylamide gel system (Life Technologies). 
The expression levels were quantified using AlphaView software. 
Semi-confluent cells, grown in 8-well chamber slides (Nalgene 
Nunc) were fixed in 4% (w/v) paraformaldehyde (Sigma-Aldrich) 
for 10 min. After three washes in PBS1X, cells were permeabilized 
10 min in 0.1% Triton, and saturated at least for 1 h with 3% BSA 
(Sigma-Aldrich) at room temperature. Primary antibodies were 
diluted in PBS1X-0.2% BSA at the desired concentration listed 
above. Cells were then washed three times in PBS1X and incubated 
with specific fluorophore conjugated secondary antibodies (Alexa 
Fluor, Molecular Probes) in PBS1X-0.1% BSA for 45 min. All the 
incubation were performed in an humidified chamber for 45-60 min 
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at RT. After last washes in PBS, slides were mounted with 
SlowFade anti-fade reagent containing DAPI (Molecular Probes).  
When indicated Magic Red Cathepsin B activity Kit 
(ImmunoChemistry Technologies, LLC, Bloomington, MN USA) 
was used to localize and monitor intracellular Cathepsin B activity 
over time accordingly to manufacturer’s instructions. Briefly Magic 
Red staining solution was added directly to adherent cells and 
incubated for 60 min at 37°C. After having removed the  medium 
the cell monolayer surface was rinsed twice with PBS, and 
eventually stained for nuclei visualization.  
Cellular staining was analyzed by Olimpus F1000 laser scanning 
confocal microscopy. 
 
12.3.1. LIST OF UTILIZED ANTIBODIES 
Anti-Microphthalmia (Ab-1) (Calbiochem #OP126L), 
Osteonectin/SPARC (Takara Clone No.OSN4-2), p21 (Santa Cruz 
Biotechnology, INC sc-817), Tyrosinase (Santa Cruz 
Biotechnology, INC sc -20035), human SCD5 synthetic peptide 
(313-327) (AnaSpec, Eurogentec Group), Rab5B (A-20) (Santa 
Cruz Biotechnology, INC sc -598), Cathepsin B (S-12) (Santa Cruz 
Biotechnology, INC sc -6493R), Caveolin-1 (N-20) (Santa Cruz 
Biotechnology, INC sc -894), CD107b/LAMP2 (BD Pharmigen 
#555803), Collagen IV (AbCam, ab*6586), V-ATPase C2 (AbCam, 
ab-176771) were used in accordance to the manufacturer’s 
instructions. β-actin Clone AC-15 (Sigma Aldrich #A5441) and α-
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Tubulin (Sigma Aldrich clone B-5-1-2 T5168) were used as western 
blot loading controls. DAPI (Molecular Probes) 
 
12.4. INTRACELLULAR pH EVALUATION 
pHRodo Red (Molecular Probes) is a weakly fluorescent dye at 
neutral pH that becomes increasingly fluorescent as the pH drops, 
allowing measurement of intracellular pH in the range 7.5–4.5, and 
was used as indicated by the manufacturers. Briefly, live cells were 
washed and incubated with 5 mM pHRodo for 30 min at 37°C. The 
addition of pH calibrators at 37 ∘ C for 5 min provides a standard 
curve to assess the intracellular pH of samples. The emission 
profiles were analysed using microplate-based fluorimetry (Victor 
X3, Wallac–Perkin-Elmer 2030 software v. 4.00). 
 
12.5. MELANIN CONTENT MISURATION 
Melanin Content Misuration was performed in duplicate at least 
twice for each cell lines. Briefly, after washing the cells with PBS, 
pellets were lysed with 100uL of 1N NaOH and vortexed repeatedly 
to homogenize. For analyses, all lysates of each cell extracts were 
transferred into 96-well plates and the relative melanon content was 
determined by optical density at 402 nm by using fluorometry 
(Victor X3, Wallac–Perkin-Elmer 2030 software v. 4.00). 
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12.6. RENILLA ACTIVITY ASSAYS 
For renilla reporter experiments, on the basis of bioinformatic 
analyses (TargetScanHuman (release 7.1, June 2016)), we identified 
one conserved putative binding site predicted to interact with 
miR221/-222 in the SCD5 3’UTR. 
The putative SCD5 seed region and its mutated version were 
respectively amplified (Table 9) by PCR (AccuTaq).  
 
 
 
After sequence analysis, these fragments were subcloned 
immediately downstream Renilla promoter into the psiCHECK 2 
modified vector (Promega). The conserved core is indicated in 
black while red letters represent the mutated nucleotides. 293FT 
cells (5x104 cells per well) were transfected with: (a) 40 ng of 
psiCHECK-3’ UTRSCD5 plasmid, (b) 50 pmol of either a stability-
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enhanced 2’-O-Methyl non targeting RNA control or miR-221 
and/or miR-222 oligonucleotides (Dharmacon Inc.), (c) 
Lipofectamine 2000 (Invitrogen). Renilla activity measured by 
using the dual luciferase assay (Promega) using Microlite LX1 
(dynatech laboratories, Inc). The wt psiCHECK-3’UTRSCD5 
cotransfected with the control non targeting oligonucleotide was 
considered as 100%. 
 
13. IN-VIVO ASSAYS 
For the in vivo assays, empty vector- or SCD5-transduced A375M 
cells in exponential growth phase were injected subcutaneously 
(s.c.) into the flank and intravenously (i.v.) at the dose of 10
6
 cells 
into adult athymic Nu/Nu mice (Charles River, Calco, Italy), 
pretreated with rat anti-mouse mAb to IL-2Rb (TMb1, a kind gift 
from Daniela Mannel, Regensburg, Germany) to deplete NK cells.  
Mice were maintained under pathogen-free conditions at the animal 
facility of Fondazione IRCCS Istituto Nazionale dei Tumori in 
Milan (Italy).  
Tumor growths were monitored twice a week. At different times 
after the injection, mice were sacrificed for necropsy and 
macroscopic metastases evaluation. In particular, lung metastases 
were counted under a stereomicroscope after staining with India 
ink.  
For 4T1 analyses, BALB/c mice were inoculated s.c. into the right 
flank, equidistant from the inguinal and axillary lymph nodes, with 
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7 × 10
3
 Tween- or SCD5-transduced cells. Tumor size was 
monitored twice weekly and the mice were euthanized when the 
tumors reached ~10 mm in diameter. For surgical excision of 
primary 4T1 tumors, mice were anaesthetized before surgery and 
tumors were resected with sterilized instruments. All mice survived 
surgery. Metastases were evaluated as previously described 
(Guiducci C., 2004). Briefly, lungs were collected and dissociated 
in Hank's Balanced Salt Solution (HBSS) containing 1mg/ml 
collagenase type 4 and 6U/ml elastase for 1 h at 4°C; organs were 
then plated at various dilutions in a medium supplemented with 6-
thioguanine. Individual colonies representing micrometastases were 
counted after 20–25 days.  
All mice were monitored carefully for signs of distress, including 
behavioural changes and weight loss. Animals were treated and 
maintained at the Istituto Nazionale Tumouri (Milan, Italy) 
according to institutional guidelines. Animal experiments were 
authorized by the Institute Ethical Committee and performed in 
accordance to institutional guidelines and national law (D.lgs 
26/2014). 
 
14. IN-VIVO ANALYSES 
Histopathology and Immunohistochemistry 
Mice tumor nodules were fixed in 10% neutral buffered formalin, 
dehydrated and finally embedded in paraffin blocks. Serial sections 
were cut at 4 µm, dewaxed, rehydrated and stained either with 
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Hematoxylin and Eosin for morphological analyses or with 
Masson's Trichrome Staining for collagen fibers detection.  
For immunohistochemical staining, heat-mediated antigenic 
retrieval protocols were used (Tris-EDTA pH 9.0 or Sodium Citrate 
pH 6.0 buffer, depending on the antibody used) followed by 
incubation with 3% hydrogen peroxide to quench endogenous 
peroxidase activity. After saturation for 10 minutes with protein 
block (Novocastra, Ltd.) the sections were incubated with primary 
antibodies. For negative controls, mouse or rabbit immune sera 
were used instead of primary antibodies. Staining was revealed with 
a polymeric system (Novolink, Max Polymer Detection System; 
Novocastra Ltd.) and visualized by using AECþ High Sensitivity 
Substrate Chromogen Ready-to-use (Dako Cytomation Liquid AEC 
Substrate Chromogen System; Dako).  
SCD5 IHC analyses were performed on five cutaneous primary 
(superficial spreading melanoma, Clark’s level III) and five lymph 
nodal metastatic samples. The bioptic melanoma specimens were 
obtained with patients’ informed consent from the archives of the 
Human Pathology Section, University of Palermo. Sampling and 
handling of human tissue material was carried out in accordance 
with the ethical principles of the Declaration of Helsinki. In 
particular for SCD5 staining was used a standard ABC technique 
(Vectastain Rabbit ABC Elite Kit). Slides were counterstained with 
hematoxylin and evaluated under a Leica DM2000 optical 
microscope. 
 Materials and Methods  
121 
 
14.1. IN-SITU HYBRIDIZATION 
Serial sections obtained from the same bioptic human melanoma 
specimens previously analyzed for SCD5, were subjected to in-situ 
hybridization to evaluate miR221/-222 expression levels by using 
miRCURY LNA microRNA ISH Optimization kit (FFPE) (Exiqon, 
Vedbaek, Denmark).  
Briefly, sections were (dewaxed) deparaffinized in xylene, 
rehydrated in ethanol solutions (100% to 70% with water) and then 
incubated with Proteinase K [5μg/mL] for 10 minutes at 37°C. After 
two washes in PBS, slides were dehydrated and air-dried. The 
appropriate double-Digoxigenin (DIG)-labeled LNA probe 
(specifically designed for miR-221 or miR-222) was prepared at the 
optimized work concentration of [40 nM] and incubated for 1h at 
the specific hybridization temperature of 54°C. LNA U6 [5nM] or 
LNA scramble [40 nM] snRNA probes were used respectively as 
positive or negative control. Slides were washed in decreasing 
stringent Saline Sodium Citrare solutions (SSC5X to 0.2X) and 
finally incubated in a humidifying chamber with blocking solution 
(PBS 0.1% Tween, 2% Sheep Serum, 1% BSA) for 15 minutes. 
Then, sections were incubated with the anti-DIG reagent 
(constituted by the alkaline phosphatase [AP]-conjugated anti-DIG 
antibody diluted 1:800 in PBS 0.05% Tween-1% Sheep Serum-1% 
BSA) for 1 hour at RT. After 3 washes in PBS-Tween 0.05%, slides 
were incubated with the AP substrate NBT-BCIP with Levamisol 
0.2mM (5-bromo-4-chloro-3-indolyl-phosphate/nitro blue 
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tetrazolium)  for 2 hours at 30°C. Staining reaction was blocked by 
washing with KTBT solution (tris-HCl 50mM, NaCl 150mM, KCl 
10mM) twice. Nuclear Fast Red was used for nuclear counter 
staining. Slides were dehydrated and analyzed at the microscopy.  
 
15. STATISTICAL ANALYSIS 
Unless indicated otherwise, all data are presented as mean±standard 
deviation (SD) and results are representative of at least three 
independent experiments. Statistical analysis was performed using 
t-test, with p<0.05 deemed statistically significant 
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